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3. INTRODUCTION 
 
In the year of 2000, the gynecological and the radiological departments at Oslo University 
Hospital, Ullevål (former Ullevål University Hospital) agreed to cooperate with the 
objective to implement two new modalities aimed to treat symptomatic uterine leiomyomas 
in a conservative manner; uterine artery embolization (UAE) and bilateral laparoscopic 
occlusion of uterine arteries (LUAO). We decided to register important preoperative and 
postoperative variables including outcome measurements of the first 100 patients treated. 
We also decided to design a randomized study to compare the two methods of treatment. In 
2003, we agreed to take part in an experimental study aimed to evaluate a completely new 
device for treatment of uterine leiomyomas; a temporary noninvasive Doppler-directed 
transvaginal uterine artery clamp (D-UAO). The studies presented in this thesis consist of 
ninety-five of these patients. 
 
3.1 Uterine leiomyomas 
3.1.1 Prevalence, morbidity and risk-factors 
Leiomyomas of the uterus is a benign tumor originating from the myometrial tissue in the 
uterus wall. Most commonly the tumor is located in the uterine body, but may also be found 
in the cervix, the broad ligament and the ovary. Leiomyomas is a major source of 
gynecological morbidity. The prevalence increases with age up to menopause (1). After 
menopause, the leiomyomas shrink (2), probably depending on decreased hormonal 
production. From an American study of serial sections of uteri, it has been estimated that up 
to 77% of women of reproductive age have leiomyomas (2). In another American study, 
1364 premenopausal women were randomly selected for ultrasound screening of the uterus. 
The estimated cumulative incidence of leiomyomas by the age of 50 was more than 80% for 
African-American women and nearly 70% for Caucasians (1). 
It is estimated that 20-50% of leiomyomas will cause symptoms (2,3).  
Leiomyomas vary in size, number and location, and the degree of symptoms is often 
depending of all these factors. The most common symptom is menorrhagia, which might 
lead to dysmenorrhoe and anemia. Large tumors independent of location may place pressure 
on adjacent organs and cause bulk sensation, urinary frequency and, less frequently, pain. 
Sometimes the only symptom is abdominal distension with discomfort and possibly 
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cosmetic complains. Leiomyomas are associated with sub-fertility, increased rate of 
pregnancy loss and risk of obstetrical complications (4-6). 
Consistently reported risk factors for leiomyoma are early menarche, nulliparity (7) and 
obesity (8,9). Lower risk is reported among smokers (10) and women who exercise more 
than 7 hours/week (11). Hormonal oral contraceptives are generally considered as relatively 
contraindicated in women with leiomyomas. However, the link between oral contraceptive 
use and leiomyomas has been inconsistently reported in different studies (12-14). The use of 
progestogen injections such as medroxyprogesterone acetate is reported to reduce the risk of 
leiomyomas (14,15). The effect of a levonogestrel-releasing intra-uterine device on the risk 
of developing leiomyomas is uncertain, however, studies have indicated that a reduced risk 
might be present (16,17). Compared with women of Caucasian, Asian and Hispanic origin, 
women of African origin have more commonly leiomyomas. Women of African origin also 
develop leiomyomas at an earlier age, have a higher frequency of multiple lesions and also 
greater sizes of the leiomyomas (1,18). 
3.1.2 Pathophysiology
The normal myometrium consists of smooth muscle cells and fibrotic tissue. Histologically, 
the leiomyomas are characterized by whirling bundles of smooth muscle cells, mimicking 
the normal muscle bundles of the myometrium. Foci of fibrosis, calcification, ischemic 
necrosis and haemorrhage may also be present (19). Degenerative changes vary inside the 
leiomyomas. The most common form is hyaline degeneration, in which the smooth muscle 
cells are replaced by collagen. Red degeneration is characterized by multifocal areas of 
recent haemorrhage that occur in women in reproductive age either taking oral 
contraceptives or who are pregnant or recently postpartum. Unlike hyaline change, the 
microscopic appearance in red degeneration shows the ghosts of the muscle cells and their 
nuclei. Later, the periphery of a leiomyoma that has undergone red degeneration may 
become white and calcified. Calcification is typical for older leiomyomas on the whole, 
commonly seen after menopause. Treatment with Gonadothropin-releasing hormone 
analogs or uterine artery embolization leads to infarct type necrosis, secondary to ischemia. 
It is characterized by finding either granulation tissue or hyalinization between the necrotic 
and non-necrotic areas, associated with recent hemorrhage. The end result is replacement of 
the infarcted area by dense hyaline tissue or calcification. For the pathologist, it may be 
difficult, however important, to distinguish the early stages of necrosis from the tumor cell 
necrosis seen in the malignant leiomyosarcomas. Other benign variants of leiomyomas like 
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the cellular and leiomyomas with bizarre nuclei (symplastic leiomyomas) are also important 
to recognize, as they can be misinterpreted as sarcomas (20,21).  
Immunohistochemical analyses of the leiomyoma vasculature have revealed higher 
microvascular density in the myometrium compared to in leiomyomas of all sizes. Vessels 
with a larger mean surface was found in myometrium and in large leiomyomas compared to 
in small leiomyomas (22). Kurjak et al. used color-Doppler ultrasound and found that the 
vascularity of the leiomyomas was dependent on tumor size, position and the extent of 
secondary degenerative changes (23). In another study, local and intra-arterial injection of 
133Xe demonstrated significantly lower blood flow in the leiomyomas compared to 
surrounding myometrium (24,25). 
The mechanism of increased menstrual bleeding in women with leiomyomas is not known. 
In a study using electron microscopic techniques, myometrium from uteri with leiomyomas 
had ultrastructural characteristics that were different from those in myometrium from uteri 
without leiomyomas (26). The myometrium in the leiomyomatous uterus has increased 
number of arterioles and venules and venule ecstasia (27). Although the venous 
abnormalities were originally thought to be due to physical compression of the vascular 
structures by bulky tumors, it is hypothesized that molecular changes leads to increased 
vessel numbers or abnormal function (28).  
Although leiomyomas seem homogenous in their macroscopic phenotype, molecular and 
cytogenetic studies have demonstrated that they are heterogeneous in their natural history 
and etiology. Differences in the amount of hormone receptors, the degree of fibrotic tissue, 
vascular changes, secretion of prostaglandins from smooth muscle cells and the expression 
of growth factor and cytokines are some of the factors that probably are responsible for the 
variable ability to grow and to induce symptoms like bleeding, pressure and pain (28).  
 
Genetics 
It is believed that a genetic element is present in the development of leiomyomas. 
Leiomyomas appear to be two-to three-fold more common in first-degree relatives of 
women with leiomyomas, compared with the general population (10). Several hereditary 
cancer syndromes predisposing to leiomyomas suggest a genetic linkage with renal cell 
carcinoma (RCC) (29). These syndromes include hereditary leiomyomatosis and RCC, 
tuberous sclerosis complex and Birt-Hogg-Dubé syndrome. The racial differences might 
also indicate that genetic predisposition play a role, and twin studies have also supported a 
strong hereditary factor (30-32). 
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Cytogenetic studies have demonstrated that most leiomyomas are monoclonal in their origin 
(33,34). The majority is cytogenically normal, however chromosomal abnormalities are seen 
in about 40% of leiomyomas. Coexisting normal and abnormal karyotypes can be found in 
one single leiomyoma and different karyotypic abnormalities can be found in multiple 
leiomyomas in the same uterus (35). It is unclear if the chromosomal aberrations are 
primary or secondary events. 
 
Theories of initiation 
The initiation process of uterine leiomyomas is not known, although there are several 
theories. One hypothesis states that increased levels of estrogen and progesterone increases 
the mitotic rate which again increases the likelihood of somatic mutations and development 
of leiomyomas (36). Richards and Tiltman used immunocytochemistry to examine the 
myometrium from leiomyomatous uteri and compared it with myometrium from normal 
uteri. They found that the myometrium of uteri with leiomyomas expresses significantly 
increased levels of estrogen receptors compared with myometrium from the non-
leiomyomatous uteri. The authors hypothesized that the pathogenesis of fibromyomata may 
be related to an inherent abnormality in the myometrium (37). Stewart and Nowak 
proposed in 1998 that leiomyoma growth were initiated through a response to injury, which 
could cause transformation of the smooth muscle cells of the myometrium from a contractile 
phenotype to a proliferative-synthetic phenotype (38). 
 
Potentiators and effectors 
Uterine leiomyomas have significantly increased concentrations of both estrogen and 
progesterone receptors compared with normal myometrium (39,40). It has long been 
established that estrogen promotes leiomyoma growth. Recent biochemical and clinical 
studies have suggested that progesterone and progestin also enhance proliferative activity in 
leiomyomas (41). Both estrogen and progesterone and their receptors seem to play an 
important role in inducing leiomyoma growth, acting closely together. There are several 
possible mechanisms for sex steroids activity in leiomyomas. 17-estradiol is found in 
higher concentrations in leiomyomas than in myometrium (42). It is speculated that reduced 
17-hydroxysteroid dehydrogenase, which normally metabolizes estrogen to estrone, may 
be a reason for this finding. The estrogen metabolite estradiol 4-hydroxylase is elevated in 
leiomyomas (43). This metabolite may function as a long-acting estrogen and possess potent 
estrogenicity. Progesterone up-regulates the estrogen receptors and also increases the 
 10
mitotic rate in myometrial tissue. These mechanisms may play a role, especially during the 
luteal phase when the progesterone level is high (8). 
There are a number of growth factors with mitogenic activity that are identified in 
leiomyomas and may be some of the effectors of leiomyoma growth. Many of these factors 
may interact, sometimes resulting in a synergetic effect. In other situations, one growth 
factor is dependent on the presence of the other. The basic fibroblast growth factor (bFGF) 
that is stored in the extracellular matrix of leiomyomas, and the transforming growth factor 
 (TGF) may play an important role. The insulin-like growth factor (IGF) stimulates cell 
proliferation in uterine leiomyomas. Other growth factors like prolactin, the vascular 
endothelial growth factors (VEGF), platelet-derived growth factor (PDGF) and epidermal 
growth factor (EGF) are also thought to take part in the process of leiomyoma proliferation 
(8). 
 
3.2 Risk of malignancy 
Sarcoma of the uterus is an uncommon malignant tumor with a generally poor prognosis. 
Since the tumor is very difficult to distinguish from a benign leiomyoma both by clinical 
and radiological examinations, concerns have been expressed about leiomyoma treatment 
that do not involve tissue specimens for accurate pathological diagnosis.   
The assumption that sarcomas do not arise from leiomyomas was supported by cytogenetic 
studies demonstrating that chromosome rearrangements in leiomyomas are distinct from the 
complex rearrangement and aneuploid karyotypes characteristic of leiomyosarcomas (44). 
However, a recent study has identified a subgroup of cellular leiomyoma with deletions of 
chromosome 1 that have transcriptional profiles that cluster with those of leiomyosarcoma 
(45). This finding has raised the theory that leiomyosarcomas may derive from certain rare 
histological and karyotypic variants of leiomyomas (46).   
The incidence of sarcomas among patients with presumed uterine leiomyoma is found to be 
low, with estimates of 0.2-0.5% (3,47,48). The common assumption that rapidly growing 
leiomyomas should cause awareness of the diagnosis of leiomyosarcoma has never been 
verified. Parker et al. found an incidence of 0.27% of sarcomas in a study of 371 women 
operated on for “rapidly growing” leiomyomas. In the same study, the total incidence of 
sarcomas among 1332 patients that had surgery for leiomyomas was 0.23%. The authors 
reviewed the literature and found that only a total of 15 (2.6%) of 580 women with 
leiomyosarcomas had a history of rapid growth. The most common symptom was abnormal 
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bleeding, followed by pain and the presence of a pelvic mass (48). The average age of 
women with a diagnosis of sarcoma is 54-63 years (49). Thus, the diagnosis should be 
considered in a postmenopausal woman with a pelvic mass, abnormal bleeding, and pelvic 
pain (50).  
 
3.3 Vascular anatomy of uterus and the ovaries relevant for uterine artery 
interventions 
A detailed knowledge of the pelvic vascular anatomy is essential to perform both uterine 
artery embolization and laparoscopic occlusion of the uterine arteries safely. Because of the 
variability of the three-dimensional distribution of the internal iliac artery branches in the 
deep pelvis, the classic anatomic and radiological topography of the uterine artery might be 
difficult to understand for the surgeon. Angiographic and surgical experience reveals 
numerous anatomical variations of the location of this artery. Sometimes there are two 
instead of one artery, the artery may be replaced by small arterial branches or it may even be 
missing at one or both sides (51,52).    
Most commonly the uterine artery arises from the internal iliac artery (hypogastric artery).  
It descends parallel to the pelvic wall until the level of the cervix where the artery 
transverses medial against the uterus and invariably crosses above the ureter. When the 
artery reaches the lateral uterine wall it divides into the ascending and descending 
(cervicovaginal) branch. The main stem of the artery ascends along the uterus at the medial 
edge of the broad ligament. For the interventional radiologist, the uterine artery is found as 
the first or second branch of the anterior division of the internal iliac artery (from the 
inferior gluteal artery) in 51% of the cases (51). The gynecologist may follow the ureter 
downwards to locate the uterine artery where it crosses above it. If uterus is large and the 
view restricted, it might be easier to follow the obliterated umbilical artery proximal to the 
origin of the uterine artery.  
Less common the uterine artery arises from the internal pudendal artery. It is crucial to be 
aware of the other parietal branches of the internal iliac artery in this area. The superior 
vesical artery often origins from the umbilical artery distal to the uterine artery, but may 
also have other locations. Similarly, the medial rectal artery and the obturator artery arise 
variably from the internal iliac artery in the same area (52). The uterus has a rich blood 
supply, mainly from the uterine artery (53). In addition, there exists a vast network of 
collateral arterial communication from the vagina, the aorta, femoral artery branches, and 
other lesser-known arterial collaterals (54,55). Collateral vessels and anastomoses often 
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become hypertrophic in the presence of uterine or ovarian lesions to supplement the 
increased vascular demand (56). 
In women with leiomyomas, two different angiographic studies have reported utero-ovarian 
anastomoses in 46% and 40% of the patients (57,58). Controversy exists about the direction 
of flow in these anastomoses. In an angiographic study of 76 patients, there was flow from 
the ovarian artery to the uterine artery in 22% of the cases, direct supply from the ovaries to 
the leiomyoma in 3.9% (57). Two other angiographic studies have revealed direct supply 
from the ovaries to the leiomyoma in 5% and 6% of the cases respectively (59,60). 
Intramural intrinsic uterine arteries consist of ascending and descending, arcuate, radial, and 
peripheral arteries leading to free flow through the uterus. Leiomyomas receive their 
primary blood supply from the end arterioles of the uterine artery (53). Bilateral occlusion 
of the uterine artery prevents collateral flow to the leiomyoma from the contralateral artery.  
 
The blood supply to the ovaries varies also between individuals. The main ovarian artery 
generally originates from the aorta below the level of the renal arteries and has a 
characteristic tortuous course when examined at angiogram (59). According to Borell et al., 
who performed angiographic studies already in 1954, the ovary is supplied from the ovarian 
arteries only in 40% of cases, both by uterine and ovary arteries in 56% of cases and by 
uterine arteries alone in 4% of the cases (61). In a recent angiographic study of women with 
leiomyomas, Razavi et al. found that the major blood supply to the ovaries was from the 
uterine artery in 6% of the cases (57). 
 
3.4 Diagnosis 
 
The diagnosis is usually made by a standard gynecological examination including 
transvaginal and/or abdominal ultrasonography. In most cases, leiomyomas have a 
characteristic appearance on ultrasonography with a sharp demarcation against surrounding 
myometrium. Commonly they appear as well-defined, hypoechoic lesions that are rounded 
in contour. The tumor may also have a more complex, inhomogeneous appearance with 
cystic changes. Usually the diagnosis is easy. However, to tell the difference from a 
leiomyosarcoma is not possible based on ultrasonography. When the leiomyoma is calcified, 
it causes acoustic shadowing that sometimes makes the visualization difficult. Saline 
infusion sonography is useful to diagnose submucous leiomyomas and is essential as 
preoperative evaluation before hysteroscopic resection. 
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Magnetic resonance imaging (MRI)  
MRI examination is increasingly being used in diagnostic of leiomyoma disease. The 
advantage of MRI is that it does not involve any ionizing radiation and that the images have 
superior contrast resolution. The disadvantage of MRI is that the examination is time and 
cost-consuming and the availability is limited. An MRI scanner consists of a large circular 
magnet housed in a gantry within which the patient lies. The system depends on the 
behavior of the hydrogen nucleus (proton) in tissues when it is exposed to radio-frequency 
signals inside a strong magnetic field. When the protons relax to its normal position, weak 
radio-signals are sent back to the receiver inside the magnetic scanner. A map of the 
distribution of the signal is built up in a computer that produces the images. The strength of 
the signals depends not only on proton density but on two relaxation times; T1 and T2 that 
represent different occurrences in the complex movement of the hydrogen proton. The T1 
and T2 weighting of an image can be selected by appropriate altering of timing and 
sequence of the radio-frequency pulses. Because the images depend on the hydrogen proton 
density in the tissue i.e. equivalent to their water or lipid content, the MR imaging is 
especially useful in the evaluation of soft tissue. 
A study performed to compare the accuracy of MRI and transvaginal ultrasonography in the 
diagnosis of leiomyomas in women scheduled for hysterectomy showed that the two 
diagnostic tools are equivalent in detecting the presence of leiomyomas. However, the study 
showed that MRI is superior in assessing the number of leiomyomas, in the diagnosis of 
adenomyosis and to measure the leiomyoma size accurate when more than 4 leiomyomas 
are present in one uterus (62). Another study compared MRI and a combination of 
abdominal and transvaginal ultrasonography in women with leiomyomas referred for uterine 
artery embolization. This study showed that MRI was superior to ultrasonography in the 
diagnosis of leiomyoma location, number of leiomyomas and volume of the uterus, however 
not in assessing the volume of the largest leiomyoma (63). The intra-observer 
reproducibility of uterus evaluation by MRI, transvaginal ultrasonography, saline infusion 
hysterosonography and hysteroscopy was compared in a study by Dueholm et al. This study 
showed that MRI was significantly less observer dependent than the other diagnostic 
techniques. Intra-observer agreement for MRI in exclusion of intracavitary abnormalities, 
detection of submucous leiomyomas and identification of leiomyomas was 0.97 for all three 
variables. For detection of intracavitary polyps, the intra-observer agreement for MRI was 
0.49 (64). The inter-observer reproducibility of MRI assessment in women with leiomyomas 
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was confirmed by Volkers et al. The investigators found also good intra-observer 
reproducibility, except for the presence of adenomyosis where a kappa-value of 0.55 and 
0.66 was found for each of two observers (65).  
Adenomyosis might be difficult to diagnose both with ultrasonography and MRI. According 
to the two above mentioned studies, MRI was found to be superior to ultrasound with regard 
to intraobserver reproducibility in the presence of adenomyosis. Both studies found an inter-
observer agreement of 0.73 for this finding on MRI. Diffuse adenomyosis is characterized 
as irregular, homogenous thickening of the endometrial-myometrial junctional zone both on 
ultrasonography and MRI. On MRI, this thickening has a low signal-intensity. Adenomyosis 
foci in the myometrium can be seen during ultrasonographic examination as heterogeneous, 
hypo-eccogenic areas with or without cysts. On MRI-examination, the foci are manifested 
as high signal intensity lesion with ill-defined margins. Byun et al. found that T2-weighted 
images were superior to T1 contrast-enhanced images in the evaluation of both the 
junctional zone thickening and the adenomyosis foci within the myometrium (66,67). 
 
Paramagnetic agents may be used during MRI examinations to produce contrast by 
decreasing T1 relaxation time in specific locations of the body. Intravenous administration 
of gadopentetate dimeglumine (gadolinium) is commonly used for this purpose. With the 
use of gadolinium-enhanced MRI, it is possible to evaluate the degree of degeneration or 
viability of the leiomyomas (68). 
Leiomyoma and uterus volume may be calculated from MR images either by the use of 
three perpendicular diameters incorporated in the equation of an ellipsoid (69,70) or by 
serial measurements of regions of interests (ROIs) on scan sequences (71). 
 
MRI measurement is a useful tool in modern research aimed at evaluating new conservative 
treatment modalities for leiomyomas. In countries like Norway, where ultrasonography is an 
integrated part of the examination performed by gynecologists, MRI examination for 
patients with leiomyomas are only occasionally indicated in daily practice. MRI 
examination is useful when the ultrasonographic diagnosis is uncertain, for preoperative 
mapping of multiple leiomyoma location before myomectomy in selected cases or in 
patients that are unable to go through a gynecological examination. 
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3.5 Indication for treatment
The most common indication for treatment of leiomyomas is menorrhagia, often 
accompanied with dysmenorrhoe and bulk symptoms. The patient’s own interpretation of 
the severity of symptoms is often the most important indication for treatment in modern 
practice. Anemia might occur, however most patients referred for treatment of leiomyoma 
symptoms including menorrhagia have hemoglobin levels within normal range (72). Urinary 
frequency is a common complaint with large uteri. Discomfort because of pressure are more 
common than distinct pain (73). Hydronephrosis or bowel constipation because of pressure 
from huge leiomyomas is  rarely seen, however such occurrences are reported in the 
literature (74). Infertility or subfertility is in some cases indication for treatment of 
leiomyomas. However, this issue is controversial and considered outside the limits of this 
thesis. 
Many women do not want to remove their uterus even though they have considerable 
complains of menorrhagia and or bulk symptoms. The reason for this is complex. Some 
women want to preserve their fertility. Other feel that the uterus is important to their feeling 
of femininity; they might be afraid of dysfunction of their sexual life, or they simply fear the 
anesthesia or the surgical procedure itself (75). 
 
3.6 Treatment options 
 
The following sections provide an overview of the current uterine-sparing treatments 
available or under investigation, including the three modalities studied in this thesis; 
Laparoscopic uterine artery occlusion, uterine artery embolization, and the transvaginal, 
Doppler-directed temporary clamp.  
3.6.1 Medical treatment 
In order to maintain organ preservation and avoid surgery, a lot of different medical 
treatment modalities for symptomatic leiomyomas are proposed.  
Nonsteroidal anti-inflammatories, oral contraceptive pills, and progestins are aimed at 
minimizing abnormal menstrual bleeding or controlling pelvic pain. These treatments are 
associated with minimal cost and risk, but their effectiveness in women with leiomyomas 
has not been systematically studied. The levonorgestrel intra-uterine device (LNG-IUS), is 
effective in reducing menstrual bleeding in women with menorrhagia with and without 
leiomyomas and should be considered as an alternative to hysterectomy in such women 
 16
(76,77). However, the use of LNG-IUS in women with leiomyomas is not investigated in 
any RCTs. The risk of spontaneous expulsion of the intra-uterine device in women with 
large leiomyomas is commonly considered as a relative contraindication to the use of the 
LNG-IUS. This occurrence is reported at various intervals in some women. However, in one 
study, the women wanted re-insertion of the device because of the remarkable effect on the 
menorrhagia (78). MRI measurements of leiomyoma and uterus volume before insertion and 
after 12 months have not shown any significant volume reduction during the use of the 
LNG-IUS (77,78). 
 
There are numerous agents investigated for the conservative treatment of leiomyomas: 
 
Gonadotrophin-releasing hormone analogs (GnRHa)  
Gonadotrophin-releasing hormone analogs with agonistic or antagonistic properties have 
been shown to reduce leiomyoma size and menorrhagia significantly (79). Although 
undoubtedly effective on leiomyoma size and symptoms, there are considerably side-effects 
that includes menopausal symptoms and bone loss (80,81). These side-effects can be 
alleviated by the use of add-back therapy with estrogens, combined estrogens and 
progestins, tibolone or raloxifene without interfering with the efficacy of GnRHa (81-85). 
Unfortunately, recurrence of leiomyoma growth and symptoms occurs rapidly after 
discontinuing the GnRHa therapy (86). This fact, together with the expensiveness of the 
drug does not make it cost-effective for common use.  
GnRHa has been used as pretreatment for myomectomy and hysterectomy, however, there 
are controversies related to the use of GnRHa on this indication. Increased risk of recurrence 
are reported, presumably because smaller leiomyomas shrink and are ignored at the time of 
surgery, only to regrow when the effect of GnRHa wear off (87). A Cochrane database 
systematic review concludes that the use of GnRHa for 3-4 months prior to leiomyoma 
surgery are beneficial for correction of preoperative iron deficiency anemia, reduce 
intraoperative blood-loss, operating-time, duration of hospital stay and rate of vertical 
incision. For patients undergoing hysterectomy, a vaginal procedure is more likely 
following the use of these agents. Evidence of increased risk of leiomyoma recurrence was 
equivocal (88). Dubuisson et al. found that treatment with GnRHa before laparoscopic 
myomectomy was one of the risk factors for conversion to laparotomy (89). Some claim that 
the GnRHa render surgical planes less distinct, making the enucleation of the leiomyoma 
more difficult (90) and the operating time is found significantly longer during laparoscopic 
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myomectomy in patients pretreated with GnRHa compared to those without (91). However, 
in an RCT subsequent to the Cochrane review, the authors did not find any differences in 
blood-loss during surgery, duration of surgery, operating time or hospital stay between 
women with and without pretreatment with GnRh-analogs. Furthermore, it was not possible 
to demonstrate any difference in cleavage planes among treated and untreated leiomyomas 
(92). A review of the cost-effectiveness of GnRh found that the costs outweigh its benefits 
(93).  
 
Androgenic steroids (Danocrine and Gestrinone)
Until GnRha became widely used in treatment of endometriosis, the androgenic steroid 
Danocrine (Danazol) was the most common medical treatment for this condition.
Four months of Danazol treatment have reduced leiomyoma related symptoms and 
leiomyoma and uterus volume with up to 37% and 30% respectively, measured by 
ultrasonography (94). Danazol has been investigated as adjuvant therapy in continuum of 
GnRha therapy because of less menopausal symptoms and no bone loss observed (95). Side 
effects including weight gain, acne and edema are reported after treatment with Danozol for 
endometriosis, however lower doses are used for leiomyoma treatment and consequently 
less side effects are seen (94). 
Another androgenic steroid, Gestrinone, is shown to reduce leiomyoma volumes and cause 
amenorrhoea, and effect of the treatment lasted up to 18 months after discontinuation of the 
therapy (96). 
 
Selective estrogen receptor modulators (SERMs)  
Raloxifen has been found to reduce leiomyoma size in postmenopausal women and in 
premenopausal women older than 40 years, however not in younger women (97). Potential 
serious side effects like thromboembolism are not fully investigated. Evidence is lacking 
regarding the usefulness and safety of this drug in leiomyoma treatment, and SERMs are 
currently not recommended for treatment of leiomyomas (98). 
Antiprogestin (Mifepristone; RU-486)
This drug is well known for the gynecologist, as it is used for pregnancy termination in 
doses of 200-800 mg with or without misoprostol. Studies including a small randomized 
controlled trial (42 patients) have shown reduction of leiomyoma and uterus volumes of 40-
50%, amenorrhoe in 40-70% of the patients, reduced anemia and leiomyoma related 
 18
symptoms and increased quality of life with doses of 5 or 10 mg. Simple endometrial 
hyperplasia was seen in 28% of the patients, less with the lowest dose. Adverse effects 
included vasomotor symptoms, however no change in bone mineral density during 12 
months follow-up (99,100). A combination of RU 486 and LNG-IUS to prevent endometrial 
hyperplasia is proposed as a future alternative treatment (101). However, the safety with 
regard to the endometrium is necessary to clarify before larger studies are performed. 
Selective Progesterone Receptor Modulators (SPRMS) 
Asoprisnil (J867) and CDB-2914 
This is a selective progesterone modulator with mixed agonist/antagonist activity that seems 
promising in leiomyoma treatment. This drug has inhibitory effect on the endometrium 
without substantial effect on the estrogen concentration. In addition, it inhibits proliferation 
and induce aptosis in leiomyoma cells (102,103). 
In a recent randomized controlled trial (phase II-study), 129 patients were treated for 3 
months with 5, 10 and 25 mg daily. Bleeding was reduced in 28, 64 and 83% of the women, 
respectively. On 25 mg dose, leiomyoma volume was reduced by 36% after 12 weeks 
measured by sonography. There were few side effects compared with placebo (104). 
Though the data are encouraging, the finding warrants replication through larger studies 
over an extended period of time. 
 
Another SPRM (CDB-2914) is recently evaluated in a phase I study (105). 
 
Aromatase inhibitors (anastrozole)  
The evidence of the use of aromatase inhibitors to treat leiomyomas are limited to case-
reports of peri- or postmenopausal women (106). The agents are unlikely to be effective in 
premenopausal women. The potential use of the aromatase inhibitor is suggested as an 
alternative to progestin in postmenopausal obese women with symptoms caused by 
leiomyomas (101). 
 
Gabergoline
Gabergoline is a dopamine agonist with inhibitory effect on the secretion of GnRh. It is 
commonly used to inhibit lactation and in treatment of prolactinoma. Recently garbergoline 
was compared with GnRha in a randomized study. The authors found significantly reduced 
leiomyoma volumes in both groups, and gabergoline had fewer adverse effects compared 
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with GnRHa (107). Clearly, further studies are warranted to determine the usefulness of this 
agent. 
 
All these substances are interesting approaches to the treatment of leiomyomas; however 
none of them are proven safe and efficient for long time use. 
 
3.6.2 Surgical treatment 
Hysterectomy 
Abdominal hysterectomy is the most frequently performed surgery for treatment of 
symptomatic leiomyomas. In 2000, 4764 hysterectomies were performed in Norway, about 
4438 due to benign disorders (108). The most common indication is leiomyomas, 
accounting for about 40% of all hysterectomies (109). Hysterectomy provides a permanent 
solution to menorrhagia and pressure symptoms related to an enlarged uterus. Complete 
relief of symptoms is found among 89% of the patients; however only 70% said that they 
would recommend the treatment to others (110). Clearly, this is a major surgical procedure 
with considerable morbidity. Recent studies have found complication rates for hysterectomy 
performed due to leiomyomas of 26% (110) and severe postoperative complications in 3.6% 
(111). The most common complication during hysterectomy is hemorrhage. A study of 446 
women having hysterectomy indicated by symptomatic leiomyomas reported higher risk of 
complications as uterine weight increased. The need for blood transfusions were increased 
when the uterus weighted more than 500g compared with uterine weight less than 500g 
(112). However, mortality rate for hysterectomy is low and was found to be 0.6/1000 in a 
retrospective study published in 1985 (113). More recent, the mortality of hysterectomy in 
women under 50 years of age with benign indications is reported to be about 0.3/1000 (114). 
Hysterectomy might be made less invasive with laparoscopic or vaginal approach. However, 
with large leiomyomas the transabdominal approach with a vertical incision is the only 
available option today.  
Myomectomy 
The most frequently performed uterus preserving surgery for leiomyomas is the 
conventional abdominal myomectomy. Myomectomy has been stated to relieve leiomyoma 
related symptoms in 80% of women (3). However, there is little documentation to support 
this statement in the literature. A prospective, non-randomized study comparing 
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myomectomy and UAE reported that 75% of the women in the myomectomy group had a 
significant decrease in symptom scores after 6 months (115). As hysterectomy, 
myomectomy is a major surgical procedure. It is widely accepted that the procedure carries 
the risk of excessive blood loss and conversion to hysterectomy. However, newer studies do 
not support these concerns (116). Even with very large leiomyomas in a study of 91 women, 
there were no conversions to hysterectomy (117). Still, in the latter study, the mean blood 
loss was 800 ml, and the highest reported blood loss was 3000 ml. In the same study, 
complications included one bowel perforation, one bladder injury and one reoperation for 
incarcerated bowel. Nevertheless, case-control studies suggest that there may be less risk of 
intraoperative injury with myomectomy when compared with hysterectomy (116,118).  
A major disadvantage of myomectomy is adhesion formation. This might compromise the 
fertility, cause pain, increase the risk of ectopic pregnancy and cause intestinal obstruction. 
In some studies with second look after abdominal myomectomy, adhesions were found in 
all patients examined (119-121). 
In studies using life-table analyzes, the average 5-year clinical recurrence-rate is found to be 
approximately 10%. It is estimated that about 50% of the patients with recurrence needed 
secondary surgery with one out of three requiring hysterectomy. In these studies, the risk of 
recurrence was increases with multiple leiomyomas, and decreased with subsequent 
pregnancies (122).  
Laparoscopic myomectomy is associated with reduced blood-loss, less febrile morbidity and 
shorter recovery time after the procedure (123). In addition, second look studies after 
abdominal and laparoscopic myomectomy have shown less postoperative adhesions (124). 
The wide application of this approach is limited because of the technical difficulty of the 
procedure especially with regard to the suturing of the myometrium. The cumulative 5-year 
recurrence rate after laparoscopic myomectomy was reported to be 51.5% in one study 
(125). Another study published a follow-up of 192 women, and found 17% recurrence after 
5 years (126). The authors concluded that the recurrence rate may be higher after 
laparoscopic than after abdominal myomectomy, but considered the low morbidity to be a 
major advantage of the laparoscopic approach. 
Adhesions may be prevented by the use of adhesion barriers both during abdominal and 
laparoscopic myomectomy. There are a number of such agents available that all seems to 
reduce adhesion formation significantly (127-130). 
Concerns have been expressed about the risk of uterine ruptures during pregnancy and 
delivery after myomectomy. The general risk of uterine rupture is found to be 0.35/1000, 
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with a risk of 6% after cesarean section and a risk of 0.02% for those who had no previous 
cesarean  (131). Spontaneous uterus ruptures have been reported, both after abdominal and 
laparoscopic myomectomy, however the incidence seems to be no higher than 1% and is 
probably dependent of a proper repair of the myometrial incision and carefulness with the 
use of electosurgery (132-135). 
There is no scientific evidence in the literature to support increased fertility after 
myomectomy for intramural or subserous leiomyomas. However, numerous observational 
studies reports pregnancy- and delivery rates ranging from 10-75% after both abdominal 
and laparoscopic myomectomy (87,136-140). Currently, myomectomy is the treatment of 
choice for women with symptomatic leiomyomas who desires fertility. 
Transcervical Resection of Myomas (TCRM)
Submucous leiomyomas may be removed hysteroscopically. If more than 50% of the 
leiomyoma is protruding into the uterine cavity and the diameter is less than 3-4 cm, it is 
considered possible to remove by a resectoscope (TCRM) (141). This procedure has low 
complication rate and short recovery time (142). However, a relatively high number of 
procedures are needed to reach the level of skills that is mandatory to perform the procedure 
safely. Approximately 10% of the patients need repeated surgery within 5 years (143,144). 
No studies have confirmed the association between submucous leiomyomas and 
menorrhagia, however, most trials show a reduction in bleeding after resection (143-145). 
Studies support an increased pregnancy rate after hysteroscopic resection of submucous 
leiomyomas compared to controls (146,147). 
 
3.7.3 Uterine Artery Embolization (UAE)
Transcatheter arterial embolization for treatment of postpartum hemorrhage was introduced 
30 years ago (148). The effect of uterine artery embolization on uterine leiomyomas was 
first described by Ravina in 1995 (149). UAE is performed by placing a catheter into the 
femoral artery and accessing both uterine arteries under angiographic guidance. To insert 
the catheter, a skin incision is made on one or both sides in local anesthesia. Embolic agents 
are then injected into the uterine arteries. Because the leiomyomas are mainly supplied by 
this artery, the procedure usually interrupts their blood supply. Most commonly polyvinyl 
alcohol (PVA) particles or Tris-acryl Gelatin Microsphers (TAGM) are used as the embolic 
agent.   
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 The procedure involves considerably post procedural pain and a substantial amount of 
narcotic painkillers are often needed the first 24 hours after treatment. The pain is thought to 
be due to global myometrial ischemia until normal myometrium establishes a new blood 
supply through collateral vessels from the adjacent organs (150). 
Postembolization syndrome occurs in approximately 40% of the patients (151,152). It is 
defined by low-grade fever, pelvic pain, nausea, vomiting, loss of appetite and malaise in 
the first week after treatment. This symptom complex is regarded as an expected aspect of 
recovery due to the necrotic process. The degree of intensity of these symptoms is variable 
and the occurrence is only regarded as a complication if unplanned medical therapy or 
hospitalization is needed (153). 
Radiation exposure to the ovaries during the procedure is estimated to approximately 22 
cGy (154). Exposure may be considerately alleviated by reducing the field size, pulsed 
fluoroscopy, limited DSA imaging and bilateral femoral puncture.  
More than 50 000 procedures have been performed worldwide (http://www.fibroids.com) 
about 30 000 of them in the US (114). Prospective single center studies have reported relief 
of excessive menstrual bleeding in 81-96% of the patients and reduction in bulk symptoms 
in 61-92% of the patients 3-24 months after treatment (151,152,155-161). Reduction in 
uterus volume of  23-53% and reduction of the dominant leiomyoma volume of 37-68% 
measured by ultrasonography or MRI are found 3-12 months after treatment (151,152,156-
159,161-164).  
In 1999, The Society of Interventional Radiology Foundation established the Fibroid 
Registry for Outcomes Data (FIBROID). This registry includes 3000 patients from 17 
treatment centers. According to the FIBROID, 82% of 1701 patients claimed satisfactory 
outcome when answering questionnaire 12 months after treatment with UAE. At the same 
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point in time, there were no improvement of symptoms in 5.5% of the patients, and 2.9% 
required hysterectomy (160). Long-term results are not published from the FIBROID, 
however, single-center studies have reported 5-year recurrence rates of 11- 20% (165-167).  
Although major complications might occur during or as a result of UAE, they are rare. The 
table shows the reported complication rates after uterine artery embolization published by 
the joint Standard of Practice Committee of the Cardiovascular and Interventional 
Radiology Society of Europe (CIRSE) and the Society of Interventional Radiology (SIR) in 
2004 (153).  
 
Complication rate for UAE (%) 
  
Transient amenorrhea                                            
 
5-10 
  
Permanent amenorrhea   < 45 years 
                                         > 45 years 
 
0 -3 
7-14 
Leiomyoma expulsion 0 - 3 
Non-infectious endometritis (chronic discharge) 1 - 2 
Endometrial or uterine infection 1 - 2 
DVT or pulmonary embolus < 1 
Uterine necrosis < 1 
Non-target embolization < 1 
Total uterine necrosis with risk of infection and sepsis may indicate acute hysterectomy. 
This occurrence is reported in 1/305 and in 3/400 in two of the early studies (151,159). The 
short-term outcome data from the FIBROID reported 3 (0.1%) hysterectomies during the 
first 30 days after admission from hospital, although the indications were not specified 
(168).  
Two cases of fatal sepsis have been published after UAE (169,170). Three other deaths has 
been reported following UAE; a case of postprocedural pulmonal embolism and two of 
unknown causes (171,172).  
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The risk of ovarian failure after UAE is believed to be caused by unintended embolization 
of a hypertrophic utero-ovarian vessel not discovered during the embolization procedure or 
by embolization of a uterine artery that provides the only blood supply to the ovary (51).  
In one recent study, where anti-Müllarian hormone measurements were used as indicator of 
premature ovarian failure, ovarian function after UAE was found to be decreased to the 
same level as after hysterectomy (173).  
Transcervical leiomyoma expulsion is defined as detachment of leiomyoma tissue from the 
uterine wall and subsequently transvaginal passage. This process is often associated with 
vaginal bleeding, discharge, abdominal pain and/or fever. Surgical intervention may be 
necessary either with D&C, hysteroscopic resection or occasionally hysterectomy. Some 
authors propose a higher risk of this occurrence with submucous located leiomyomas. 
However, this is questioned by others (153,174). 
Gynecologists have expressed concerns about adhesion formation after UAE. In a case-
control study of 30 hysterectomies after UAE, there were significantly more patients (20%) 
with adhesions in the group with previous UAE compared to 1.4% among the controls 
(175). 
 
The absolute contraindications to UAE are ongoing pregnancy or infections. Suspicion of 
malignancy in the uterus or ovaries would be a contraindication, unless the procedure aims 
to palliate such a condition. 
Relative contraindications to any endovascular intervention include coagulopathy, contrast 
material allergy and renal impairment. Relative contraindication to uterine artery 
embolization would be conditions that reduces the normal healing process; 
immunocompromise, chronic endometritis, previous pelvic radiation or surgery (153). 
Desire to maintain childbearing potential is still a relative contraindication, since 
preservation of fertility cannot be assured according to the existing literature. However, 
there are several pregnancies reported after UAE. Walker et al. reported 56 pregnancies 
after 1200 embolization procedures, of which 33 (58.9%) had a successful outcome (176). A 
randomized study compared fertility outcome of 40 women after myomectomy and 26 after 
UAE who tried to conceive. There were significantly more pregnancies (83%), labors (48%) 
and fewer abortions (18%) after myomectomy than after embolization (65% pregnancies, 
19% labors, 53% abortions). However, the study was obviously not randomized on the basis 
of desired pregnancy (177). For women who wish to maintain childbearing potential, UAE 
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may be performed as treatment for leiomyoma symptoms if hysterectomy is the only 
alternative option. 
There are different types of embolic agents available. In the first published series, PVA 
particles were used. The outcome with the use of this agent was satisfactory on both short 
and long term (165,166). More recently tris-acryl gelatin microspheres (TAGM) have 
shown the same level of durable symptom control (178). Resorbable gelatin sponge particles 
have been used by Katsumori et al. in a trial with 96 patients. Eighty patients were followed 
up to 5 years with a recurrence rate of only 11% and reintervention rate for all reasons of 
13% (167). The use of spherical PVA have been investigated in different protocols with less 
satisfactory results (179,180). 
Factors associated with outcome of clinical symptom relief and leiomyoma reduction short 
time after UAE have been investigated by many authors. Pretreatment leiomyoma diameter 
of more than 8.5 cm measured by ultrasound were associated with more clinical failures in a 
study of 300 patients followed for 5 months (181). This finding could not be confirmed by 
MRI examination of 114 women and 2 years follow-up in another study (182). However, 
Spies et al. found, after adjustment for other variables; that larger baseline dominant 
leiomyoma volume on MRI measurements before treatment was associated with less 
bleeding reduction. In addition there were less reduction in leiomyoma volume after 3 and 
12 months in the same group of patients (183).  
Submucous location of the leiomyomas before treatment was found to result in significant 
larger uterus volume reduction measured by MRI 3 months after treatment compared to 
other locations in two studies (183,184). Any certain link to clinical result was not found 
(182,183,185,186). 
The vascularization of the leiomyomas has been examined by gadolinium-enhanced MR 
images before treatment in several, however small, trials. All studies indicate that 
leiomyomas that are well perfused before UAE treatment respond better to UAE treatment 
than poorer perfused leiomyomas (184,185,187).  
The T1 and T2 signal characteristics of the leiomyomas before treatment have by some 
authors been reported to be an important predictive sign of leiomyoma volume response to 
treatment. Two authors have claimed that a high signal intensity on T1-weighted images and 
a low signal-intensity on T2 weighted images before treatment corresponded with less 
reduction on leiomyoma volume after treatment (187,188), and one found only this 
association for the T1-weighted image (184). Watson and Walker found that high signal 
intensity on T1-weighted images was uncommon and did not appear to alter the outcome. 
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They found, however, among 114 women examined, that high pretreatment signal intensity 
on T2 weighted sequences was associated with a good response on volume reduction and 
patient outcome. A low signal intensity was associated with less shrinkage, but good 
outcome for the patients symptoms (182). 
Several investigators have claimed that complete leiomyoma infarction after treatment is 
essential to avoid regrowth of leiomyomas and recurrence of symptoms both on short-term 
(189) and long-term recurrences (190,191). It is reasonable to assume that this statement is 
correct, however the number of cases studied is limited, and adjustment for other variables 
is not performed. Thus there is not yet any scientific evidence to confirm this assumption. 
There is limited evidence of predictive factors on long term result. Spies et al. reported 
clinical outcome of 3-60 months follow-up in 200 patients. The authors found higher risk of 
failures with baseline leiomyoma volume larger than the median, among those not improved 
at 1 year and three times higher risk of failure for women with less than or equal to median 
percent reduction of leiomyoma volume at 3 months after UAE (165).  
Gabriel-Cox et al. studied data from 562 women from 8 different treatment centers with a 
follow-up of median 4.8 years after UAE. They found that only unilateral uterine artery 
embolization predicted subsequent hysterectomy with a relative risk of 2.19. Age, 
indication, uterine-volume, embolic agent or radiologist experience did not influence on the 
hysterectomy rate (192). 
 
Comparison with myomectomy and hysterectomy 
Comparison with myomectomy have shown shorter hospital stay and recovery time 
(115,193,194) and less in-hospital complications after UAE (115,193,195). Symptom 
reduction is reported with larger variations; UAE was better in one study (196), similar in 
another (115), better with regard to menorrhagia and poorer for bulk symptoms in a third 
(194).  
Three randomized controlled trials have compared UAE with hysterectomy. Shorter hospital 
stay and less time to full recovery after UAE were found in all studies (197-199). 
Complication rate is more variably reported. Two of the studies concluded with less 
complications after hysterectomy, and one found less major complications after UAE 
compared to hysterectomy (199). The latter finding was supported by a large retrospective 
multicenter (HOPEFUL) study (200). The HOPEFUL study found that the hysterectomy 
group reported more complete relief of their leiomyoma-related symptoms; however that 
only 70% of the participants in this group would recommend the procedure to a friend 
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compared to 86% who would do that after having experienced UAE. Cost-effectiveness 
analyses over a period from 1 to 5 years after treatment favors UAE in studies from Europe, 
USA and Canada (199,201-204). In a Chinese setting, You and co-writers found 
hysterectomy more cost-effective over a 5-year period compared to hysterectomy and 
myomectomy (205).  
 
3.6.4  Myolysis
A number of focused energy delivery systems based on radiofrequency, bipolar electricity, 
Yag-laser, microwaves and cryogenic probes have been investigated to destruct leiomyoma 
tissue (206-208). Delivery of the energy is applied transvaginal or during laparoscopic or 
hysteroscopic guidance. Clinical evaluation has mainly been confined to case series with 
apparent effect on leiomyoma size and reduction of bleeding symptoms (209,210). Although 
uneventful deliveries are reported after myolysis treatment (211), most investigators do not 
recommend this treatment for women who desire pregnancy because of potential risk of 
uterus rupture, abnormal placenta development and adhesions (212). Longer term 
comparative trials are required to evaluate and compare myolysis with other leiomyoma 
treatments. 
MR-guided high intensity focused ultrasound (MRgFUS) is performed by interventional 
radiologists (213). A focused high-frequency, high-energy ultrasound beam is used to 
thermally destruct leiomyoma tissue. The extent of treatment is supervised by a MRI-based 
volume and thermal real-time measurement system. Although the treatment is performed 
without incisions and with a very fast recovery for the patients, there are considerable 
limitations of the use. Only small parts of the leiomyoma have been treated at a time in the 
published studies, and the need for additional therapy appears to be high (214). MRgFUS 
cannot be used on leiomyomas located near sensitive organs like bladder or the bowel. In 
addition, the procedure is time-consuming and the equipment needed to perform the 
procedure is expensive. However, if the technique continues to develop and further studies 
are performed, the modality may find a place in the field of non-invasive leiomyoma 
treatment. 
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3.6.5 Laparoscopic bilateral occlusion of uterine arteries (LUAO)
In a Nordic paper published in 1895, Kuhn refers to the first reported procedure of surgical 
uterine artery occlusion as treatment for leiomyomas and menorrhagia. This procedure was 
performed by Rydygier and published in Wiener Wochenschrift in 1889.  
Kuhn himself reports 34 cases performed by 8 different surgeons in Denmark and Norway 
(215). Follow-up was 1-12 months. Nineteen patients had good effects on bleeding 
reduction and leiomyoma size. For nine patients the follow-up result was stated as “a 
positive impression”. One had no effect. One had recurrence of symptoms after 3 months; 
another had recurrence after 12 months. Three women had some, but not complete effect of 
the treatment. The technique used was ligation of the left and right artery by vaginal 
approach in 32 cases, and by open abdominal approach with additional closure of the round 
ligament and the ovarian ligament in 2 cases.  
                  Since this initial report, the use of this treatment modality has been only occasionally 
reported until the first description of the modern variant of this treatment modality in 2000 
(216,217). By laparoscopic approach and bipolar coagulation, Liu et al. occluded the uterine 
arteries and the anastomotic sites of the ovarian arteries. The authors published the year 
after a 7-12 months follow-up on the first 87 patients and reported that 93% of the patients 
had reduced menstrual bleeding. Ultrasonographic measurement of uterus and leiomyoma 
volume reduction was 46% and 76% respectively (218). Smaller studies, with a follow-up of 
3-36 months have reported similar results, however the leiomyoma volume reduction in the 
studies by Holub and Simsek was 48 and 49% 12 months after treatment measured by 
ultrasonography and MRI (219-221). Simsek et al. used the pictorial blood loss assessment 
chart (PBAC) and found significantly reduced score (43%) among 21 patients 12 months 
after treatment. All authors have reported very moderate pain after the treatment. 
Complications have been reported to be minor, however only one paper describes the 
complications after laparoscopic occlusion systematically (222). Holub et al. investigated 
114 patients treated at 2 endoscopic centers in the Czech Republic retrospectively. No 
intraoperative complications were registered. A total of eight patients (7%) experienced 
postoperative complications within 30 days after surgery, with one of the women 
experiencing two complications, resulting in nine complications. In 5 patients, six early 
postoperative complications occurred: One port site bleeding, 4 patients with fever was 
successfully treated with antibiotics and one woman had sign of obturator nerve affection 
that was resolved with anti-inflammatory drugs and electostimulative convalescence 
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therapy. In addition, two patients were reported to experience leiomyoma necrosis that was 
treated with hysterectomy in one and myomectomy in the other. In addition, one patient was 
diagnosed with an endometrial stromal sarcoma one year after the laparoscopic treatment 
(222). 
Recurrence of symptoms occurred in 10 (9%) of 114 patients 24 months after treatment in 
one study and in 27 (28%) of 95 patients after 48 months in another study (222,223). 
Pregnancies after treatment with LUAO have been reported (223-225). One author have 
expressed concerns about a relatively high rate of early miscarriages, however, no cases for 
control were provided in that study (224). In another study, pregnancy outcome in 34 
patients after UAE and laparoscopic occlusion of the uterine arteries were compared. In this 
study, higher rates of early miscarriages were found after UAE compared to after 
laparoscopic uterine artery occlusion (226). However, the appropriateness of both these 
treatment modality for women who desire fertility is still unclear.  
Studies that compare outcome of symptom relief, volume reduction of uterus and 
leiomyomas or recurrence rates with other uterine sparing treatments are not published, with 
exception for the papers presented in this thesis. 
 
3.6.6 Temporary Doppler-directed transvaginal uterine artery occlusion (D-UAO)
 
Transvaginal occlusion of the uterine arteries can be performed by placing a specially 
designed clamp in the vaginal fornices and, guided by Doppler ultrasound auditory signals, 
positioning it to occlude the uterine arteries (227). Such a clamp has been developed to 
temporarily occlude the uterine arteries in order to treat uterine leiomyomas. The clamp is 
left in place for 6 hours and then removed. 
Similar to UAE and LUAO, this treatment is based on the principle of depriving 
leiomyomas of blood supply to cause tissue death. The rational basis for a temporarily 
occlusion to treat leiomyomas is based on the theory of transient uterine ischemia (150). 
According to this theory, only a certain period of time of ischemia is necessary to cause the 
death of leiomyomas because they are more vulnerable to ischemia than the surrounding 
normal myometrium. Perfusion studies by MRI and computer tomography performed after 
uterine artery embolization indicates that blood initially clots in the vessels of both 
myometrium and leiomyomas. After a period of time, the blood clots disappear inside the 
vessels of healthy myometrium, but not inside the vessels in the leiomyomas (150). The 
myometrium survives until blood flow is re-established, but during the time the 
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myometrium is ischemic the leiomyomas die due to its insufficient blood supply. It is 
hypothesized that the leiomyoma tissue are less able to lyse clots that form inside the vessels 
after ischemia and also less able to recruit collateral flow. Findings of a greater amount and 
higher activity of fibrinolytic enzymes in normal myometrium compared to leiomyomas 
support this theory (228). The greater micro vascular density in the myometrium compared 
to the leiomyomas may contribute to this, since the fibrinolytic enzymes are concentrated in 
the endothelium of the vessels (22,229).  
If the uterus survives severe ischemia and the leiomyomas do not, the next question will be; 
how long time of ischemia is necessary to cause leiomyoma death? 
Reports of CT scans with the use of contrast medium performed 6 and 24 hours after uterine 
artery embolization showed wash-out of medium from myometrial tissue, indicating that by 
this time the reperfusion of the myometrium had already started. The same scans showed 
contrast medium still trapped inside the leiomyomas, and no wash-out (230). In another 
study, contrast-enhanced MRI was performed within 30 minutes after UAE. Immediately 
following embolization, there was a dramatic reduction in the overall uterine perfusion, 
however, while perfusion of the myometrium reduced from a maximum enhancement 
(ME90) of 110 before embolization to a ME90 of 26% immediately following embolization, 
the perfusion of the leiomyomas had virtually stopped. After 1 and 4 months, perfusion in 
the myometrum recovered to normal levels, while leiomyoma perfusion remained extremely 
poor (231). The investigators state that the immediate difference in perfusion response 
between myometrium and leiomyomas is most likely a result of collateral circulation and 
the size of the vessels supplying the myometrium since the myometrial vessels tend to be 
larger (22,232).  
The rationale for the six-hour duration of the occlusion with the vaginal clamp is derived 
from a study of laparoscopic bilateral uterine artery permanent occlusion with pH-
measurements of the myometrium in continuation of the procedure. The pH-values 
measured indicated that the myometrium was reperfused within six hours after occlusion of 
the uterine arteries in about 80% of the patients (233). 
A subsequent study in 10 women with laparascopic treatment of leiomyomas documented 
that the clamp was kept in place for a time period of between 10 to 59 minutes in all of the 
ten patients (234). 
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4. AIMS OF THE STUDY 
 
This study aims to explore uterine-sparing treatments for women with symptomatic uterine 
leiomyomas. We wanted to investigate alternative modalities to occlude the uterine arterial 
supply. 
 
More specific, we aimed to 
 
1. Investigate the short and long term effect of bilateral laparoscopic occlusion of  
uterine arteries compared to uterine artery embolization. 
 
2. Compare the 6-month MRI results of laparoscopic occlusion of uterine 
arteries with uterine artery embolization and investigate how the results related to the 
clinical outcome.   
 
3. Determine whether it was feasible to occlude the uterine arteries temporarily by a  
Doppler-directed vaginal clamp. 
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5. MATERIALS AND METHODS 
 
5.1 Approvals 
The studies had approval from the Regional Committee for Medical Research Ethics in 
Eastern Norway and from Ullevål University Hospital’s Advisory Committee on the 
Protection of Patient Records. The study protocol for the randomized study presented in 
paper II and V were published at the www.clinicaltrials.gov website (NCT00277680). 
5.2 Patient selection and pre-treatment evaluation 
 
The patients were recruited among premenopausal women with symptoms of uterine 
leiomyomas referred to the university clinic, who expressed a desire to avoid hysterectomy. 
Inclusion criteria were the women’s own interpretation of increased amounts of menstrual 
bleeding (menorrhagia) and/or pressure symptoms. The preoperative examinations included 
a gynecological examination, ultrasonography, cervical smear and endometrial biopsy. 
Exclusion criteria included suspicion of malignancy, active pelvic inflammatory disease, 
known adenomyosis, menopause as well as pregnancy or desire for future pregnancy stated 
by patient. Additional exclusion criteria were uterus size exceeding the umbilical level and 
subserous leiomyomas that could easily be removed by laparoscopic surgery. Submucous 
leiomyomas with a diameter of less than 3.5 cm with an intramural extension of more than  
50% were considered more suitable for hysteroscopic resection and were therefore 
excluded. Patients on hormones, specifically estrogens, progesterone, gonadotropin- 
releasing hormones or birth control pills within the last two months were also excluded. 
 
Specific inclusion criteria for the study presented in paper III and IV were age above 18 
years and no use of IUD, any intravaginal pessaries or other devices. The gynecologist had 
to be able to locate the position of both uterine arteries during Doppler ultrasound 
examination.  
 
Specific exclusion criteria for the studies presented in paper I, II and V were 
contraindications against surgery and age less than 30 years. 
 
Written informed consent was obtained from all the participants when it had been 
established that they met all eligibility criteria. 
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5.3 Randomization  
(Paper II and V) 
Randomization of 1:1 was undertaken in a total of seven blocks of 10 patients, using sealed 
envelopes. Five envelopes in each block of ten were assigned to laparoscopic treatment and 
five to uterine leiomyoma embolization. The envelopes in each block were closed, mixed 
and then numbered. Treatment was decided by drawing the next available envelope in 
ascending numerical order. 
 
5.4 Outcome measures
Pictorial blood loss assessment chart (PBAC)
This was the primary outcome variable in paper I and II, and one of the secondary outcome 
variables in paper III and IV.  
PBAC is a self administered pictorial chart, which, in addition to record the number of 
sanitary pads and tampons used, also takes into account the degree to which individual items 
are soiled with blood, passage of blood clots and episodes of flooding. After the inclusion 
into the studies, the women were given the chart together with oral and written instruction 
for use. The chart was filled in by the participants during the last menstrual period prior to 
treatment, as well as in advance of each outpatient appointment up to six months after the 
initial treatment. The participants were encouraged to use the same type of sanitary pads 
and/or tampons during the study period. The percentage change in pictorial blood loss 
assessment chart score for each individual was calculated and compared in order to 
minimize possible bias generated by women using different types of sanitary pads and 
tampons. 
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 Pictorial Blood loss Assessment Chart (English version for illustration) 
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Patient assessment of symptoms 
Paper I, II and V: Symptoms of menorrhagia and pressure were recorded using a simple 
standardized questionnaire by outpatient visits. The participants were asked to grade their 
bleeding amount as “little”, “moderate”, “heavy” or “very heavy”. Bulk symptoms 
including urinary frequency were recorded “yes” or “no”. The patients were also asked to 
grade changes in bleeding and bulk symptoms as “better”, “worse” or “unchanged” 
compared to pre-treatment condition. 
Paper V: The original consent included a 6-month follow up. Patients with no primary 
failure signed consent for extended follow up at this point. We surveyed the study 
participants about their present leiomyoma related symptoms by outpatient visits, telephone 
or letter to the patients at 12 months and thereafter annually until hysterectomy or 
menopause. The same questionnaire as described above was used, however this time with 
additional questions about menopause and subsequent leiomyoma related treatment. In cases 
of increasing bleeding, an endometrial biopsy was performed to exclude malignancy. 
Symptom recurrence was defined as new symptoms or worsening of symptoms that 
occurred more than 6 months after treatment, with or without repeated intervention. 
Postoperative pain and nausea measured by a visual analogue scale (VAS):
(Paper I and II)  
A visual analogue scale was used to evaluate the postoperative pain, nausea and headache. 
Every 4th hour the first 12 hours after treatment and then every 6th hour the next 24 hours, 
the patients were asked to set a mark on a 10 cm long line depending on their own 
perception on the severity of symptoms. They were told that the beginning of the line 
represented no symptoms and that the end represented the worst imaginable symptoms. 
There was no scale or mark on the lines. After the patients were admitted from hospital, one 
of the investigators (KH) measured the length in cm from the beginning of the line to the 
patient’s mark. The average length, number of marks, the maximum symptom score and the 
time for the maximum symptom score were registered.  
Postoperative painkilling regime (Paper I and II): All patients received a fixed regime of 
postoperative painkillers that contended of a nonsteroidal anti-inflammatory drug 
(diclofenac suppositories 50 mg three times/24 hours) and a paracetamol-codeine phosphate 
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combination (paracetamol 800 mg + codeine 40 mg four times/24 hours). The ketobemidon 
was given in variable doses by a patient-controlled intravenous pump.  
Duration of hospital stay (Paper II): All patients were told that the expected stay in the 
hospital was 2 days. The actual stay was recorded for all participants. 
Recovering time (Paper II): All patients were given 14 days of sick-leave or (if they did not 
have any paid employment) they were told that they needed 14 days to full recovery. The 
actual time to recovery or return to work was recorded at the one-month- or three-month 
visit.
Complications (Paper I and II): All in-hospital complications were recorded at the time of 
admission from the hospital. At the follow-up consultations, all adverse events that had 
occurred since the last visit were recorded. All subsequent surgical and medical 
interventions as well as readmission to the hospital or prolonged hospitalization were 
recorded as adverse events.  
Definitions
Clinical failures (Paper I and II): Clinical failure was defined as persisting symptoms, 
worsening of symptoms or new symptoms with or without further treatment during the first 
six months after the initial treatment. In paper V, clinical failure during the first six months 
after treatment is referred to as “primary clinical failure” to avoid confusion with the term 
“clinical recurrence”. 
Clinical recurrence (Paper V): Clinical recurrence (or “symptom recurrence”) was defined 
as new symptoms or worsening of symptoms that occurred more than 6 months after 
treatment, with or without repeated intervention. 
 
Magnetic resonance imaging (MRI)
(Paper I, III, IV, V) 
MRI examination of uterus and leiomyoma was performed before treatment in all patients. 
In the studies reported in paper I, II and V, the MRI examination was repeated after 1, 3 and 
6 months. In the study reported in paper III and IV, MRI examination was reiterated the day 
after treatment and after 3 months. MRI studies were performed with a 1.5T Magnet 
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(Gyroscan NT Intera Philips, Best, The Netherlands). Using turbospin echo (TSE), T1-
weighted pulse sequence images were obtained in the transverse plane. With the use of T2-
weighted TSE sequences, imaging was performed in the transverse and the sagital plane. 
Transverse fast-field echo (FFE) images were acquired in optimal plane through the 
dominant leiomyoma after rapid intravenous administration of gadopentetate dimeglumine 
0.1 mmol/kg/body weight (Magnevist, Schering AG, Berlin, Germany). Images were 
obtained every 5 seconds between 30 and 180 seconds after contrast injection. Finally, 
delayed TSE axial T1 images were obtained immediately after the FFE sequence. The total 
uterine volume and the volume of the largest leiomyoma were calculated from the sagittal 
and the transverse T2 images. The volume of the dominant leiomyoma and uterus were 
calculated using the formula for a prolate ellipsoid (Lenght×Width×Depth×0.5233), as 
described by Orsini et al. (70). Regions of interest (ROI) were placed in normal 
myometrium, middle of dominant leiomyoma, and the gluteus muscle. When leiomyoma 
was heterogeneous, the ROI was expanded to include a larger area. The T1 (and T2) 
properties of the leiomyomas were normalized using skeletal muscle for correction: T1=T1-
leiomyoma/T1- skeletal muscle (184,235). The maximum enhancement index was 
calculated from the T1 images before and after contrast medium was given: [(T1 peak-T1 
before)/T1before] x 100. The degree of infarction after treatment was estimated visually 
from the contrast enhancement images and categorized into complete infarction of all 
leiomyoma tissue with no enhancement, partial infarction with inhomogeneous or partial 
enhancement in one or some leiomyomas, and no infarction in any leiomyoma with 
unchanged enhancement from pretreatment examination. The number and location of 
leiomyomas > 2 cm were recorded. Submucous and subserous leiomyomas were classified 
according to a modification of the classification described by Wamsteker et al.(141). 
Pedunculated leiomyomas without intramural extension were classified as type 0 
submucous or subserous leiomyomas, respectively. When the intramural part of the 
leiomyoma was less than 50%, the leiomyoma was classified as type I. With an intramural 
extension of 50% or more, the leiomyoma was classified as type II. If the leiomyoma had 
contact with both the endometrial cavity and serosa, it was classified as transmural. The 
term “transformation of uterus” was used in cases with multiple leiomyomas where there 
was difficult to find normal myometrial tissue or to define one single dominant leiomyoma.  
In paper V, we have used a simplified version of this classification with only leiomyomas 
type 0 and I presented as submucous or subserous. 
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5.5 Interventional Procedures 
5.5.1 Laparoscopic bilateral occlusion of uterine arteries
(Paper I, II and V) 
 
The patient was placed in the supine position without flexion of the hips. No cervical 
tenaculae was used. Under general anesthesia with tracheal intubations, a 10 mm trocar was 
inserted in the midline below the initial incision and two 5.5-mm trocars were inserted 
ipsilateral to the epigastric artery. The peritoneum between the round ligament and the 
infundibulopelvic ligament was incised with a scissor parallel to the external iliac artery. 
The retroperitoneal space was entered by blunt dissection. Atraumatic forceps were used to 
reach the lateral origin of the uterine artery. The obliterated umbilical artery was identified 
on the anterior abdominal wall. It was firmly grasped with a forceps and lifted to show its 
posterior part. Then the umbilical artery was dissected from the posterior location caudally 
towards its unobliterated part, that continuous into the internal iliac vessel. In this area, the 
origin of the uterine artery was found. Then the uterine artery was dissected towards the 
uterus to confirm that the artery was crossing over the ureter and then entering into the 
uterine wall. The uterine artery was occluded lateral to the ureter with one or two endoclip. 
In some cases, the internal hypogastric artery was occluded with a clip on one or both sides 
in addition to the occlusion of the uterine arteries. Finally, the utero-ovarial collateral 
arteries located in the utero-ovarial ligament were bilaterally coagulated using a bipolar 
forceps. 
Clamping of the uterine artery. 
(Photo by dr.Langebrekke, for illustration purposes only.The patient is not included in the study) 
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5.5.2 Uterine Artery Embolization  
 
(Paper I, II and IV) 
 
Unilateral right femoral artery was punctured and a sheath with inner diameter of 1.3 – 1.7 
mm placed. The uterine arteries were intubated with a 65 cm long catheter with cobra curve. 
The catheter was gently placed using a soft and angled Teflon-coated wire. After placement 
the catheter was connected to a pressure transducer. If spasm was noticed by pressure drop 
or slow antegrade flow in the uterine artery 200 μg nitroglycerin and/or nifedipine 5 mg was 
injected intraarterially; if still spasm an 1 mm microcatheter was placed and the Cobra 
catheter pulled back into the hypogastric artery. The only diagnostic angiography performed 
was the ones to place the catheter into the right position. Both the uterine arteries were 
embolized with 355-500 μm polyvinyl alcohol particles (Contour, Boston scientific). The 
particles were mixed with contrast and nitroglycerin and injected slowly during fluoroscopy 
with 2-10 cc syringes until flow was nearly stopped. No further proximal occlusion with 
coils or gelfoam particles was performed.  
 
5.5.3 Temporary Doppler-directed transvaginal uterine artery occlusion 
(Paper III and IV) 
A prototype of the Doppler-directed, transvaginal uterine artery clamp system Flowstat® 
(Vascular Control Systems Inc, San Juan Capistrana, CA) was used. The system consists of 
a guiding cervical tenaculum, a transvaginal vascular clamp with integrated Doppler 
ultrasound crystals and a small battery powered transceiver that generated audible Doppler 
sound.  
The uterine arteries were located by the use of the audible Doppler signals, and occluded 
with the vascular clamp.  
 
The patients were placed in the lithotomy position in a standard gynecology treatment room. 
Nine patients were treated in paracervical blockage with addition of intravenously sedation 
while one patient was in general anesthesia when applying the clamp. The paracervical 
block was performed with injection of 20 ml bupivacaine (Marcain, AstraZenica, Oslo, 
Norway) at the 9:00 and 3:00 lateral cervical position, and a Schroeder tenaculum was 
applied to the cervix at the 6:00 cervical position.  
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 The guiding tenaculum was placed in the 12:00 cervical 
position, and the Schroeder tenaculum was removed. The 
transvaginal clamp was attached to the guiding tenaculum. 
With help of the guiding tenaculum, the clamp was slid 
upwards along the vaginal mucosa close to the uterine body to 
the level of the vaginal fornices at the 9:00 and the 3:00 
cervical position. When the clamp reached the uterine arteries, 
the crystals on the arms of the clamp return audible signals 
from the right and the left arteries.   
The clamp was advanced further along the guiding tenaculum, 
displacing the uterine arteries superior to the point of insertion 
into the uterus. Then the clamp was closed. The absence of 
audible Doppler signals from the uterine arteries indicated that 
the uterine arteries were occluded bilaterally. The clamp 
remained in place for six hours.  
Angiographic examination was performed with clamps in 
position. A 5F pigtail catheter was placed into abdominal aorta 
at the level of the renal arteries through right femoral artery 
puncture. Patency of the uterine arteries as well as collaterals 
through the ovarian arteries was evaluated. After the initial 
aortography we waited until the renal pelvis and the ureters were filled with contrast to 
evaluate for any obstruction of the ureters. When the uterine arteries were not occluded, the 
clamp was repositioned and the aortography repeated.  
 
5.5.4 Preoperative preparation 
Immediately prior to embolization and laparoscopy (paper I, II and V), one single dose of 
cefalotin 2 g (Keflin, Eli Lilly & Co, Indianapolis, Ind) and metronidazol 1.5 g (Flagyl, 
Aventis Pharma AS, Lysaker, Norway) as well as suppositories diclofenac 100 mg 
(Voltaren, Novartis Norge AS, Oslo, Norway) and paracetamol 800 mg + codeine phosphate 
(Paralgin Major, Weifa AS, Oslo, Norway) were given. 
One hour prior to the vaginal clamping procedure (paper III and IV), one dose of rofecoxib 
50 mg (Vioxx, MSD, New Jersey, US) per-orally and one dose of suppository paracetamol 
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500 mg (Paracet, Weifa AS, Oslo, Norway) were given. Just before treatment, the patients 
received one intramuscular injection of ketorolac 30 mg (Toradol, F. Hoffmann-La Roche 
Ltd, Basel, Switzerland). 
 
5.6 Statistics 
The data are presented as mean values for normal distributed data and as median values for 
skewed data. A two-sided t-test was used for comparisons of a continuous variable in two 
patient groups if the variable in question did not have a markedly skewed distribution. If the 
distribution was markedly skewed, a two-sided Wilcoxon-Mann-Whitney test was used. A 
paired t-test or Wilcoxon signed ranks test was used for comparison of paired data. A chi-
square test or Fisher exact test was used when comparing categorical variables. The 
cumulative rates of recurrence and hysterectomy over time were calculated and compared 
using Kaplan- Meyer curves and the log-rank test. A significance level of 0.05 was used for 
all tests. For the papers I, II and V, we used the data program SPSS (SPSS Institute Inc., 
Chicago IL). 
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6. SUMMARY OF RESULTS 
Paper I. Laparoscopic occlusion of uterine vessels for the treatment of symptomatic 
leiomyomas. Initial experience and comparison to uterine artery embolization 
This prospective non-randomized study reported our initial experiences with 22 patients 
treated with laparoscopic bilateral occlusion of the uterine arteries and 24 patients treated 
with uterine artery embolization. The paper describes in detail the technique that we have 
used for both laparoscopic bilateral occlusion of the uterine arteries and uterine artery 
embolization in later studies included in this thesis. The treatment groups were not similar; 
the preoperative uterine size was larger and the body mass index was higher among patients 
treated with embolization compared to those treated with laparoscopy. 
We found that all 22 laparoscopic procedures and 23 of the 24 embolization procedures 
could be successfully carried out. Due to bilaterally spasm in the uterine arteries, one of the 
embolization procedures could not be completed. After laparoscopic occlusion of the uterine 
arteries, the percentage reduction in PBAC scores at 1, 3 and 6 months were 37%, 52% and 
50% respectively. After the embolization procedures, the percentage PBAC reductions at 
the same points were 64%, 63% and 67%. The volume of the dominant leiomyoma was 
reduced with 36% and the uterus volume was reduced with 37% 6 months after treatment 
with laparoscopy evaluated with MRI measurements. After UAE, the corresponding volume 
reductions were 45% and 40%. No comparisons between the treatments groups were 
performed for any of these variables. Pain registration by a visual analog score (VAS) scale 
was 1.4 cm after laparoscopy and 1.9 cm after embolization (P=0.40). The amount of opioid 
painkillers (ketobemidon) needed was significantly lower after laparoscopy with 16 mg 
compared to 38 mg after embolization (P<0.001). There were no peroperative complications 
in either of the treatment groups. Complications after laparoscopic occlusion of the uterine 
arteries occurred in 4 patients. There were one pulmonary embolus and 3 cases of temporary 
skin- and adductor muscle disturbances suspicious of affected obturator nerve. After 
embolization, four cases of post-embolization syndrome occurred; three with mild 
symptoms that resolved within 8 days, and one with more severe symptoms of relapsing 
fever and discharge. The latter one eventually accepted hysterectomy and a fistula between 
the appendix and the uterine cavity was found.  
Secondary surgery was necessary in 5 additional patients. In the laparoscopy group one 
hysterectomy and one hysteroscopic resection of the endometrium was performed because 
of lack of effect of the primary treatment. In addition, one hysteroscopic resection was 
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performed because of expulsion of leiomyoma tissue. In the embolization group there were 
two cases of leiomyoma expulsion that resulted in hysteroscopic resection in one and 
dilatation and curettage in the other. 
 
Paper II: Laparoscopic Occlusion Compared With Embolization of Uterine Vessels: A 
Randomized Controlled Trial 
We randomized 66 patients to either embolization or bilateral laparoscopic occlusion of the 
uterine arteries. The clinical result 6 months after treatment was compared. Fifty-eight 
participants received treatment; 29 with embolization and 29 with laparoscopy. The primary 
endpoint – the percentage PBAC difference between pre-treatment and 6 month registration 
– did not differ between the groups, with mean 53% reduction after laparoscopy and 52% 
reduction after embolization. However, the 80% power of the study was only 52% to detect 
a difference in PBAC reduction of 20%. Bleeding reduction was reported among 25 patients 
(86%) after laparoscopy and among 26 patients (90%) after embolization (P=0.69) 
However, when differentiating the bleeding amount, significantly more patients complained 
about heavy menstrual bleeding 6 months after treatment in the group treated with 
laparoscopic occlusion of the uterine arteries compared to the group treated with 
embolization, 6 (21%) versus 1 (4%), (P=0.04). There were no other statistically significant 
differences regarding the symptom relieve between the two treatment groups. Clinical 
failure was seen in 6 (21%) subjects after laparoscopy and in two (7%) subjects after 
embolization (P=0.13). 
Significantly less pain and nausea were observed after laparoscopy than after embolization 
during the first 48 hours after treatment. On a visual analog scale ranging from 0 to10, the 
maximum pain score was 3.7 after laparoscopy and 5.5 after embolization (P=0.010). The 
maximum nausea measured on the same scale was 2.8 and 5.4 respectively (P=0.007). Less 
use of ketobemidon was seen after laparoscopy (12 mg) compared to after embolization (46 
mg), P<0.001. The duration of hospitalization varied significantly, with an average of 46 
(24-72) hours after laparoscopy and 57 (24-108) hours after embolization (P=0.001). The 
median sick leave duration was 21 days after both treatments. Additional treatment was 
necessary in six patients (21%) after laparoscopy and in seven (24%) after embolization. 
Five subjects in the laparoscopy group and two in the uterine artery embolization group 
needed further treatment for persistent menorrhagia (P=0.42). Expulsion of leiomyoma 
necessitating secondary surgery occurred in one patient after laparoscopy and in five after 
embolization (P=0.19).  
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Vaginal discharge more than 10 days was experienced by four patients after laparoscopic 
occlusion compared to by ten patients after embolization, the difference was not significant. 
Serious complications occurred only in the laparoscopy group with one pulmonal embolism 
and two cases of temporary obturator nerve affections also reported in paper I. In addition, 
one woman had symptoms of claudication from the right buttock after bilateral occlusion of 
the hypogastric artery and was successfully treated with balloon angioplasty. Other 
complications were minor. 
 
Paper III: Multiple Myomas Treated With a Temporary, Noninvasive, Doppler-
Directed, Transvaginal Uterine Artery Clamp 
This paper is a case report describing a successful treatment with a new device placed 
vaginally to temporarily occlude the uterine arteries. A 43 year-old woman with uterine 
leiomyomas and symptoms of menorrhagia, dysmenorrhoa and pelvic pain was treated with 
a vaginal clamp for 6 hours. MRI examination 3 months after treatment showed 49% 
reduction in uterus volume and 77% reduction in leiomyoma volume. The PBAC score 
decreased from 139 before treatment to 117 at three-month follow-up.  
 
Paper IV: Treatment of Uterine Myomas with Transvaginal Uterine Artery Occlusion: 
Possibilities and Limitations 
This experimental feasibility study included 10 patients. The uterine arteries were occluded 
bilaterally for 6 hours by the use of a vaginal clamp. During the occlusion, eight of the 
patients went through an angiographic examination. We found angiographic evidence of 
bilateral occlusion of the uterine arteries in 4 of the patients. One of these was excluded 
from further participation because of collateral blood-flow to the leiomyomas. The 
remaining three patients had reduced or no blood-flow to the leiomyomas the day after the 
procedure measured by contrast-enhanced MRI. Two of these three had remaining symptom 
control for 24 and 48 months with reduced menstrual bleeding measured by patients self-
reporting and PBAC. The leiomyoma reduction was 87% and 39% measured by MRI 3 
months after treatment. Two patients did not go through angiographic examination. One of 
these reported good clinical effect of the treatment, however slightly increased uterus 
volume was seen at 3-month MRI. She was followed for 12 months until menopause. The 
other one had increased uterus volume and still menorrhagia at 3-month control and went 
through uterine artery embolization 15 months after vaginal occlusion treatment. On 
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angiographic examination we found that two of the procedures occluded the ureter 
unilaterally. The hydroureter and hydronephrosis resolved itself within a week. 
 
Paper V:  Uterine artery embolization versus laparoscopic occlusion of uterine arteries  
for leiomyomas: Long term results of a randomized comparative trial 
This is the long-term follow-up of the patients reported in paper II. In this study we 
compared the recurrence rate after UAE and LUAO. In addition, we investigated the MRI 
changes 6 months after treatment related to the two different treatments and the clinical 
outcome. Of the 58 patients who participated in the randomized study reported in paper II, 
50 had no clinical failure at 6 months. This group of patients was followed for median 48 
months (8-73) until hysterectomy or menopause. We surveyed the study participants 
annually about their leiomyoma related symptoms by outpatient visits, telephone or letter. In 
the initial study, all patients did go through MRI examination before intervention with either 
UAE or laparoscopic occlusion. Forty-eight of the fifty women with no primary failure at 
six months went through MRI examination at that time. We found a higher cumulative 
clinical recurrence rate after LUAO with 14 recurrences (48%) compared to after UAE with 
5 recurrences (17%), log-rank test, P=0.02. The cumulative 5-year hysterectomy rate was 
also higher after laparoscopic treatment compared to after UAE, 8 (28%) versus 2 (7%), 
P=0.041. The MRI- measurements showed a significant larger uterus volume reduction with 
mean 51% after UAE compared to 33% reduction after laparoscopy (P=0.001). Contrast 
enhanced MRI examination revealed complete leiomyoma infarction in all patients treated 
with UAE and in only 5 patients treated with laparoscopy (P<0.001). Among 11 patients 
with recurrence, regardless of initial intervention, uterus volume was reduced with mean 
24% compared to 48% in the 37 patients with no recurrence (P=0.004). Incomplete 
infarction of leiomyomas was seen in 73% (8/11 patients) in the recurrences group versus 
24% (9/37 patients) in the non-recurrence group (P=0.009).
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7. GENERAL DISCUSSION 
7.1 Patient selection 
All patients included in the studies were recruited among patients referred from their private 
gynecologist or general practitioner to the university clinic because of symptoms of uterine 
leiomyomas requiring therapy. Some of the patients in paper I were allocated to a specific 
treatment based on uterine size, since all patients with a uterine size exceeding the umbilical 
level were assigned to embolization treatment. The baseline characteristics of the patients in 
that study were also otherwise different, e.g. the body mass index was different between the 
two treatment groups. This implies that the two treatment groups were not completely 
comparable. 
However, the primary purpose of the study reported in paper I was to explore the uterine 
artery occlusion method in a pilot study and to investigate if it was possible to compare the 
two treatment modalities in a randomized study later. The patients reported in this paper are 
a mix of the first 10 patients in a non-randomized pilot study (5 patients in each treatment 
group), 9 patients that did not want to participate in a randomized trial or by whom the 
uterus was too large according to the eligibility criteria, and the first 27 randomized patients 
that were treated. In this first study, because of the diversity of the patients participating, we 
chose not to perform statistical analyses to compare the two treatment groups with regard to 
the main outcome variables. We realize, however, that it might be questioned that we used 
data from some of the randomized patients reported in paper II together with the other non-
randomized participants from paper I.  
 
7.2 Methodological considerations  
 
7.2.1 Sample size and power calculation 
The primary endpoint that was chosen for the randomized study presented in paper II was 
the percent reduction in menstrual bleeding 6 months after treatment measured by pictorial 
blood loss assessment chart. The sample size was calculated under the assumption that a 
20% difference in pictorial blood loss assessment chart score between the groups would be 
of clinical significance. Based on a standard deviation of 27 for the percentage change in 
PBAC, 30 patients were needed for each treatment group to define a statistically significant 
difference with a power of 80%. Sixty-six patients were enrolled to take allowance for a 
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drop out rate of 10%. The standard deviation for the percentage change in PBAC score was 
chosen based on one of the authors (OI) earlier studies of PBAC changes after transcervical 
resection (non-published data). However, when calculating the percentage change in PBAC 
score in this study, the actual standard deviation was found to be 37. Thus, the power of the 
study with respect to the PBAC difference was only 52%. Due to the low power of the 
study, definite conclusions regarding the main efficacy variable (PBAC reduction) could not 
be drawn. With the actual standard deviation, it might be shown that a sample size of 110 
patients is necessary to detect a difference of 20% for this variable. 
 
7.2.2 Inclusion period 
Patients in the randomized study were included between December 2000 and December 
2004. The first patient was treated at the end of December 2000 and the last patient was 
treated in April 2005. This is a long inclusion period due to difficulties in finding patients 
willing to undergo randomization between two treatments. In addition, the study was 
stopped for 6 months between April and October 2003 because of a serious event after one 
embolization procedure. One patient, not included in any of the presented studies, was 
admitted to the department 5 days after uterine artery embolization with signs of bowel 
perforation. She went through an emergency operation, but unfortunately died in septical 
shock 7 days after the initial treatment. All uterine artery intervention treatments were 
stopped until medical and legal investigations were finished. Finally, the investigations 
concluded with bowel perforation because of a malignant tumor in the colon sigmoid not 
associated with the embolization treatment, and the study was allowed to restart. 
The long inclusion period could possibly have biased the randomized study. There might 
have been differences in the referral policy, in the patient population or in the treatment and 
nursing offered in the department. These factors have to some extent been neutralized by the 
nature of the randomized design of the study. The protocol was not changed during the 
study, and there was no change in the technique or instruments used for the interventions 
neither during the embolization nor during the laparoscopic procedures. However, there 
might have been some differences in the way the general anesthesia was performed during 
the laparoscopic procedures since the anesthesiologists changed during the study period. In 
addition, the MR images were digitalized during the time of the trial. One radiologist (ABB) 
that took part in the evaluation of the MRI examinations in the start of the study started to 
work in another hospital and did not continue as investigator after paper I was published; 
 50
however, all other investigators both in the gynecological and the radiological department 
remained constant during the study period.  
 
7.2.3 Randomization 
The manual method that we used for randomization might be questioned. Concerns have 
previously been expressed about violation of the random principle during assignment to 
treatment by use of sealed envelopes during the randomization procedure (236). The 
alternative would be to use a random number generator either from tables or by use of a 
computer program to complete the randomization within the blocks. However, these 
services are expensive and were not available at the hospital when the study was performed. 
 
7.2.4 Implications of a non-blinded design
Since none of the studies were blinded, the registrations of the patient’s subjective 
symptoms, the satisfaction, the postoperative pain and nausea, the duration of hospital stay 
as well as the number of additional interventions might have been biased. One of the 
investigators (KH) that also performed the laparoscopical procedures did look after most of 
the patients during the hospital stay as well as she saw the majority of the patients for the 
controls. This might have influenced these variables. 
Also the evaluation of the MR images could have been influenced by the readers. All MR 
images were initially read by radiologist with experience in gynecological radiology. After 
the six-month follow up, all examinations were reviewed by one of the two radiologists 
(HJN, NEK). One of them (NEK) performed most of the uterine artery embolization 
procedures. Both were blinded to the included groups, but quite early it was obvious to the 
observers which group the patient belonged to from the contrast enhanced images.  
 
7.2.5 Strength of the study 
It is generally accepted that new treatments should be evaluated in randomized controlled 
trials. However, many new surgical modalities are implemented without comparative 
studies. This thesis present the first randomized study of laparoscopic occlusion of uterine 
arteries compared to uterine artery embolization. 
 
7.2.6 Outcome measures 
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PBAC measurements
PBAC is a semi-subjective outcome measure, depending partly on the women’s own 
perception of blood-loss. The exact amount of blood-loss is not measured. The 
discriminatory power of the PBAC as a diagnostic test for menorrhagia has previously been 
questioned (237). However, it is demonstrated that the method is superior to a woman's full 
subjective perception and assessment of menstrual blood loss without a chart, even if PBAC 
is performed only once, and the consistency when women assess a second period appears to 
be high (238). Discrimination between menorrhagia and normal menstruation was not 
intended in our study. The treatment was decided based on the women’s own perception of 
symptoms, which also is how menorrhagia usually is managed in clinical practice (72).  
A more accurate method to measure the periodic blood-flow would be the alkaline hematin 
method, which is commonly used as the golden standard for this purpose. The method 
involves, however, considerable inconvenience both for the patient and the doctor, since the 
patient have to collect all her used sanitary pads and tampons and bring them with her to the 
doctor, which in turn have to extract the blood for analyses. The use of this method to 
estimate the periodic blood-loss would most likely have reduced the response and 
compliance in the study. The Society of Interventional Radiology (SIR) recommends the use 
of PBAC measurements in scientific reports involving uterine artery embolization (239). 
The original validation of pictorial blood loss assessment chart (240) was performed using 
standardized sanitary pads and tampons. Women in our study used their own regular 
sanitary pads and tampons and this could possibly have generated bias in the results. To 
reduce this bias, the women were encouraged to use the same brands and sizes of pads or 
tampons throughout the study period. In addition, only the percentage reduction in pictorial 
blood loss assessment chart for each subject was used in the analyses. 
 
 
Evaluation of pain, nausea and the amount of ketobemidon used 
We tried to minimize the possible bias connected to these measurements by the use of a 
fixed painkilling regime as the basis medication and with additional narcotics 
(ketobemidon) that was patient-controlled. However, because of the marked differences in 
the nature of the interventions, that required general anesthesia in one (laparoscopy) and 
only local anesthesia in the other (embolization), the total amount of painkilling medication 
did vary between the groups and also within different patients within the same group. To be 
more certain to have eliminated the effect of medicaments given during the interventions, it 
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might have been better to measure the pain, nausea and ketobemidon used the day after the 
procedure. 
 
MRI-examinations
The protocol included MRI examinations at 1, 3 and 6 months after the study intervention 
procedures. Only the 6-month measurements are used in the analyses because those were 
the most complete ones. There were a considerable number of missing or incomplete 
examinations at 1 and 3 month-examination. Together with the limited number of patients 
studied, we found that these result would be difficult to evaluate.   
During the study two improvements took place which affected evaluation of the MRI. The 
digital storage system, the PACS, was implemented in the department and thereby stored the 
MRI pictures. The digitalized images made it easier to review the images. Also, at the time 
we started we were only able to scan the uterus with three slices during contrast 
enhancement imaging. It was therefore possible to miss some of the myomas at follow-up. 
These changes took place after the first 15 study-participants had been through MRI 
examination. This implicates that the earliest MRI evaluations are less reliable than the later 
ones. 
The calculations of uterus and leiomyoma volume were performed by the use of three 
perpendicular diameters incorporated in the equation of an ellipsoid. The accuracy of uterus 
volume assessment by use of the ellipsoid formula based calculation has been evaluated 
against the parallel planimetric MRI method as a standard. The investigators found that the 
ellipsoid formula based calculation has excellent performance and is considerable less time-
consuming, and is therefore to be preferred in studies evaluating treatment of uterine 
leiomyomas (235).  
 
Follicle Stimulating Hormone (FSH) measurement 
FSH was taken before and after treatment. After publication of paper I, we did not use these 
measurements further in our analyses. We realized that the FSH would spontaneously vary 
considerable in the age group of patients in our studies. In addition, the FSH value varies 
considerably during the menstruation cycle (241). To obtain a standardized parameter for 
ovarian reserve, the blood-samples must be collected at the 3rd day in the cycle (242). This 
standardization was difficult to obtain in our patient group, partly because of patient 
compliance, irregularity in the cycles and sometimes permanent vaginal bleeding, especially 
prior to the interventions. To obtain a more reliable measurement of the patients hormonal 
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status and the ovarian reserve reduction after treatment, one could have used the cycle-
independent anti-Müllarian-hormone (AMH) (243,244). After consideration, we decided to 
use only the clinical evaluation (amenorrhoea) as a parameter on menopause. 
7.2.7 The intervention procedures 
 
Laparoscopic occlusion technique 
According to the protocol, the utero-ovarial anastomotic sites were coagulated in addition to 
division of the uterine arteries in order to avoid collateral perfusion to leiomyomas. When 
we started to perform the procedure, we used the technique originally described by Liu et al. 
(217), that included coagulation of the utero-ovarian ligament. As described in the 
introduction chapter, angiographic studies have visualized flow from the ovaries to the 
uterine artery and leiomyomas in about 25% of patients (57). This additional procedure 
during surgery might possibly have increased the risk of ovarian failure, since the blood-
supply to the ovaries is found solely from the uterine artery in 4-6% of women (57,60). 
Holub et al. compared LUAO with and without coagulation of the utero-ovarian 
anastomoses in a non-randomized, prospective study of 90 patients with a mean follow-up 
of 16 months. The authors did not find any statistically significant differences with regard to 
symptom reduction, leiomyoma reduction or subsequent interventions between the groups 
of patients. However 6 (9%) secondary surgeries were performed in the group of 67 patients 
without anastomoses occlusion compared to none in the group where the anastomoses sites 
were closed. The authors report normal FSH levels in all patients 3 months after treatment 
and no patients with menopausal symptoms (245).   
 
Uterine Artery Embolization  
During the embolization procedure, the field size was limited in order to reduce the 
radiation exposure. Thus, we have no information of the presence or not of ovarian 
collaterals.  
 
Controversies exist about the choice of particles during the embolization procedure. Our 
protocol for uterine artery embolization included the use of PVA particles. Those were the 
first embolic agents used for UAE (151,246) and long-term results are good (165,166). 
Spherical embolization particles such as TAGM have been developed for use in the 
neuroradiological field, in which calibration of the embolization agent is crucial. A better 
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distribution of TAGM compared to non-spherical agents like PVA has been observed in 
animal models (247). It is argued that the irregular shape and large granulometric size range 
of the conventional PVA particles result in more clumping and less predictable level of 
arterial occlusion compared to the calibrated TAGM (247,248). Because embolization of the 
uterine arteries is based on the preferable flow to the leiomyomas, it is important to avoid 
spasm (249). Microcatheters are often used to avoid this, and Spies et al. found that 
nonspherical PVA particles were more likely to cause obstruction in these catheters 
compared to spherical TAGM (250). 
We have not used microcatheters routinely, but 4-F catheters. To avoid spasm, the PVA-
particles were mixed with nitroglycerin. Still, if spasm occurred, injection of nitroglycerine 
and/or nifedipine or microcatheter was used. 
It is claimed that small nonspherical PVA particles contra calibrated spheres would affect 
normal myometrium more extensively and cause more post procedure pain (251). Studies 
comparing the use of the two different agents could not support this theory (252,253). 
 
Another issue discussed among interventional radiologists is which angiographic endpoint 
to use in order to achieve devascularization of the leiomyomas without unnecessary damage 
to the myometrium (“overembolization”). With the use of TAGM for uterine artery 
embolization, a limited embolization technique was introduced. This technique uses the 
angiographic endpoint described as “near-stasis“ with the common uterine artery still patent 
and all distal portions occluded (249). The limited embolization protocol is thought to 
reduce the necrosis in the myometrium and cause less pain and discomfort for the patients. 
However, no studies have confirmed this theory.  
The treatment protocol at the time the study presented in this thesis was started described 
the established method with the angiographic endpoint “stasis” or “near-stasis” and reflux of 
contrast medium towards the uterine artery origin. With the importance of maintaining 
constancy during the study in mind, we did not find evidence that justified a change in the 
technique or in the embolic agent used during the study period.  
Temporary Doppler-directed transvaginal clamp 
The manufacturer of the clamp has changed since the study was performed. The new 
manufacturer has made small changes to the design of the clamp: The shape on the tip of the 
clamp is modified to perform a better and more reliable grip on the tissue. 
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7.2.8 Statistics 
Intention to treat/ per protocol analyses 
In paper II, we analyzed the result both according to the principle of intention to treat and 
per protocol. However, we excluded the patients that were randomized, but did not receive 
any of the interventions, from all our analyses including the intention to treat analyses. 
According to Fergusson et al. post-randomization exclusion will not bias the result of 
intention to treat analyzes in cases of premature randomization and for patients that do not 
meet the eligibility criteria if they never received the intervention (254). This is the case for 
the eight patients in question and we found it reasonable to exclude them. 
 
Missing values
Six patients had missing PBAC scores in the analyses in paper II, two in the embolization 
group and four in the laparoscopy group. Since the reduction in PBAC was set to zero in 
these cases, according to the intention to treat principle, there might have been slightly 
better results regarding this variable in the laparoscopy group if all values had been present.  
 
7.3 Interpretation of the result 
Paper I, II and V 
Paper I, II and V report the results of treatment with laparoscopic occlusion of the uterine 
arteries and uterine artery embolization. The first study (paper I) confirmed the feasibility of 
both treatments in our hospital. We found significantly reduced leiomyoma and uterus 
volumes measured by MRI, as well as reduced menstrual bleeding, measured by PBAC after 
both treatment modalities compared to before treatment. The laparoscopic procedure 
involved significantly less need for narcotic painkillers. This was confirmed in the next 
study (paper II) in which the patients were allocated to the two treatment groups by 
randomization. In addition, significantly more pain and nausea was found in the randomized 
study. The finding of shorter hospital stay after laparoscopy compared to after embolization 
(paper II) supported this result, although the recovery time after treatment was not shown to 
be different. We thought that the smaller amount of pain after laparoscopic occlusion could 
be partly due to more collateral vascular supply to the uterus compared to after 
embolization. When analyzing the MR images (paper V) six months after treatment, we 
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 We did not compare the PBAC-reduction in the first non-randomized trial (paper I). In study 
number two (paper II), the patients were allocated to the two different treatments by 
randomization, and the percentage PBAC reduction 6 months after treatment was used as 
the primary endpoint. There was no difference between the study groups when comparing 
this variable. Unfortunately, as discussed above, the study reported in paper II was 
underpowered with regard to the PBAC measurement, and thus we could not draw any 
conclusion regarding the most effective treatment based on this variable. 
However, significantly more patients did complain of heavy bleeding six months after 
treatment. The latter variable is an even more subjective assessment than PBAC, and very 
weakly correlated to the actual amount of bleeding (255). According to Warner et al., the 
perception of heavy bleeding could still be of value since it probably takes into account 
more than the total blood volume. This could be difficulties with the containment of blood 
flow and associated symptoms or acute unmanageable blood flow in the first few days (72). 
We did see that in three patients who still complained of heavy bleeding after six month, 
which was not classified as primary clinical failure because of improvement of symptoms 
and initially no need for subsequent treatment, recurrence occurred with extended follow-up 
(paper V). 
 
At 6 months after treatment (paper II), we found a tendency of more clinical failures after 
laparoscopic occlusion of the uterine arteries, with 6 cases compared to 2 cases after 
embolization, but the finding was not statistically significant. The lack of significance with 
regard to this numbers might have been caused by the low number of participants studied. 
When analyzing the long-term follow up of the patients (paper V), the cumulative 
recurrence rate was found significantly higher after treatment with laparoscopic occlusion 
compared to after embolization, which may lead to the assumption that also the difference in 
primary failures would have been statistically significant with an appropriate sample size. 
The 6-month MRI-results reported in paper V revealed significantly less infarcted 
leiomyomas in the group of patients treated with laparoscopy compared to the group treated 
with embolization. It is possible that a larger study with a sufficient sample size also would 
have showed minor or no difference in the short time result after the two treatments, and 
that the higher recurrence rate after laparoscopy reported in paper V is due to 
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revascularization of the leiomyomas after a period of time. Several authors have stated that 
incomplete infarcted leiomyomas will have the ability to regrow and cause recurrence of 
symptoms with time (190,191). Kroencke et al., however, studied two different 
embolization protocols and proposed that incomplete infarcted leiomyomas that was seen at 
MRI examinations 24-72 hours after embolization did cause early failure and repeat 
interventions already after 3 months follow-up, although the number of patients in their 
study was small and no statistical analyses were given (189). Contrast-enhanced MRI 
examination early after the treatments would perhaps have given us more information aimed 
to discuss these mechanisms. 
 
The complications reported in paper I and II after both laparoscopy and embolization are of 
importance. The case of pulmonal embolism that occurred one week after laparoscopy was 
probably induced by surgery. The patient had no known increased risk of thromboembolism 
before treatment. The alternative option for the patient would have been embolization or 
hysterectomy, which both carries the risk of thromboembolism (256-258). We do not think 
that we exposed the patient to a greater risk by offering her the laparoscopic treatment. The 
temporary obturator nerve affections that were seen in three patients (paper I and II) 
occurred in the beginning of the study. We think that this complication was due to our lack 
of experience with the surgical procedure and that either a hematoma or too rough 
manipulation of the nerve caused this unfortunate problem for the patients. The same 
complication is also reported by one other author after difficult dissection in relation to an 
absent uterine artery (222). Claudication of the gluteal muscle as a result of hypogastric 
occlusion was unexpected (paper II), usually there are enough collaterals for a sufficient 
blood supply to the pelvis after closing the hypogastric artery (259). This complication 
illustrates the diversity of the functional pelvic vascular anatomy and the importance of 
carefulness when surgery is performed in this area. 
After uterine artery embolization, there were 5 patients with prolonged fever and pain, 
diagnosed as postembolization syndrome (paper I and II). This is expected when compared 
with other studies (151,153). One of these patients needed a hysterectomy. A necrotic uterus 
and a fistula between appendix and the uterus were found during surgery. Total necrosis of 
the uterus is a rare, however known, complication to both embolization and laparoscopic 
occlusion of the uterine arteries (222,260). 
Expulsion of leiomyomas is well recognized after uterine artery embolization 
(152,246,261). It is discussed in the literature whether this occurrence should be regarded as 
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a complication (174,262) or not. Some authors do not recommend performing uterine artery 
embolization in patients with submucous leiomyomas because of the assumed risk of 
expulsion and subsequent surgery (263). Others see the advantage of faster and more 
complete restoration of the uterus (174,264).We included all submucous leiomyomas that 
were not suitable for hysteroscopic resection. This resulted in 6 (21%) leiomyomas with 
submucous location in each treatment group. Thus, the relatively high number of subsequent 
interventions indicated by leiomyoma expulsion reported in paper I and II, may be caused 
by our selection of patients.  
Menopause occurred only in women older than 45 years during the study period. However, 
we have not evaluated the ovarian reserve after the two treatments. Clearly, both treatments 
might have carried risk of ovarian damage because of the techniques used. In patients 
treated with laparoscopic occlusion of the uterine arteries, the additional coagulation of the 
utero-ovarian collaterals may have reduced blood-flow to the ovaries. In those treated with 
UAE, risk of non-target embolization of ovarian collaterals existed.  
 
In addition to the difference that we found between the groups with regard to the degree of 
infarction of the leiomyomas, there was also significantly less volume reduction of the 
uterus in the group treated with laparoscopy compared to the group treated with 
embolization (paper V). Also when comparing the groups with recurrence and those 
without, regardless of treatment, and when comparing the patients with and without 
recurrence in the laparoscopy group, we found the same result. Although the sample size 
was too small to perform analyses to adjust for other variables (265), our findings support 
previous statements about the association between recurrence and both smaller post-
treatment volume reduction and incomplete infarcted leiomyomas (165,266).  
 
Less favorable results after laparoscopy with regard to recurrence of symptoms, less 
infarcted leiomyomas and less reduction of uterus volume could be explained by technical 
surgical failure as discussed in paper V. Two authors have reported less recurrence after 
laparoscopic occlusion of the uterine arteries than we have found. Holub et al. reported 9% 
recurrences in 114 patients 24 months after treatment (222). Wang et al. followed the 
patients for 48 months and reported 27 (28%) recurrences in 95 patients treated with 
laparoscopic occlusion (223). The preoperative volumes of the uterus and leiomyomas are 
not given in any of these studies, which make the selection of patients difficult to compare. 
The surgical procedure in our patients was sometimes challenging with large uteri and 
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restricted view. The relatively high number of surgery related complications might reflect 
this. We have evidence of one surgical failure because of insufficient occlusion of the 
uterine artery on one side. This patient experienced recurrence of symptoms and went 
through angiographic examination as preparation for uterine artery embolization as 
secondary treatment (paper II). Since the protocol did not include angiographic examination 
after surgery, we do not know if there are more similar failures. 
Another possible reason for the poorer results after the laparoscopic treatment may be the 
more proximal occlusion of the uterine artery and less injury to the distal smaller vessels 
compared to what the particles during the embolization procedure causes. This could leave a 
greater amount of collaterals left open or with better ability to expand.  
 
Paper III and IV 
Paper III and IV report the experimental feasibility study of the transvaginal temporary 
vascular clamp. The case reported in paper III demonstrated that it was possible to achieve 
effect of the treatment on symptoms with short follow-up, and the MRI measurements 
confirmed devascularization and reduction in leiomyoma volume. However, this was only a 
case-report and could not tell us anything about how many patients that would benefit from 
the treatment. The more distal occlusion of the uterine arteries provided by the clamp 
compared to what was the case during the laparoscopic occlusion could theoretically result 
in more favorable effect with the clamp treatment. On the other hand, uncertainty exists 
with regard to the necessary duration of the occlusion. The rationale for the 6-hours duration 
of the clamp is as described in the introduction, the time needed for the myometrium to 
reperfuse after permanent occlusion of the uterine arteries by laparoscopy (233). There are 
no studies that evaluate the effect of occlusion in different periods of time.  
In paper IV, the difficulties of applying the clamp correctly without affecting the ureters 
were demonstrated. In addition, the visualization of collateral supply from the ovary in one 
patient illustrated one limitation of this treatment modality, although the small number of 
patients studied prevents us from any estimations of how many patients this would affect. 
We think that one of the reasons for the difficulties of applying the clamp correctly was 
large leiomyomas that involved the isthmus or cervical area, and thus modulating the course 
of the uterine artery. However, even with a different selection of patients and successful 
technique, there will be the issue of collaterals, in particular, the utero-ovarian anastomoses 
and small existing collaterals that may expand and reduce the success rate even with a 
perfect application of the clamp. On the other hand, when compared to laparoscopic 
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permanent occlusion of the uterine arteries, where similar limitations exists, the transvaginal 
temporary placed clamp provides a much less invasive modality of treatment that, even with 
a lower successes-rate compared to embolization of the uterine arteries, could be attractive 
to some patients. 
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8. CONCLUSION 
We found that laparoscopic permanent occlusion of the uterine arteries had effect on 
symptoms caused by uterine leiomyomas on short-term follow up in the majority of 
patients. The treatment also induced shrinkage of leiomyomas and uterus size measured by 
MRI 6 months after treatment in most patients. However, the risk of recurrence appears to 
be high: We found a 48% cumulative 5-year recurrence-rate in our study. In addition, 
surgery-related complications were significant.  
 
The comparison to uterine artery embolization in a randomized study showed no difference 
in outcome 6 months after treatment measured with PBAC reduction as the main outcome 
variable. However, the study was underpowered with regard to this variable, and no definite 
conclusions could be drawn. Comparison of 6-month MRI results revealed larger number of 
patients with complete infarcted leiomyomas and more shrinkage of the uterus size after 
uterine artery embolization compared to after laparoscopic occlusion of the uterine vessels. 
The long-term follow-up of the same study showed a significantly better clinical outcome 
after embolization with 5 (17%) clinical recurrence compared to 14 (48%) recurrence after 
laparoscopy. Hysterectomies were also significantly fewer after embolization, and were 
necessary in 2 (7%) patients compared to 8 (28%) after laparoscopy. 
 
Analyses of the MRI results after both embolization and laparoscopic occlusion of the 
uterine arteries supported the notion that incomplete infarcted leiomyomas and smaller post-
treatment volume reductions are associated with higher recurrence rates.  
 
In the experimental study of a temporary, noninvasive Doppler-directed, transvaginal clamp 
aimed to treat symptomatic uterine leiomyomas there were technical difficulties with regard 
to applying the clamp correctly. We were only able to confirm the correct placement of the 
clamp in half of the patients by angiographic examination. We found some indication of 
treatment effect on contrast-enhanced MRI examination the day after the procedure and one 
patient had also good clinical effect up to 24 months after treatment. The risk of occluding 
the ureter during the application of the clamp was confirmed by the angiographic 
examination. The efficacy and safety of the clamp needs further evaluation.  
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9. RECOMMENDATIONS 
 
Based on our studies, we would recommend uterine artery embolization instead of 
laparoscopic occlusion of uterine arteries to most women with symptoms caused by uterine 
leiomyomas where hysterectomy or myomectomy is not the option. 
 
Laparoscopic occlusion of uterine arteries may be evaluated in further studies as an 
additional procedure during surgery aimed at reducing intra-operative blood-loss and 
recurrence rate after myomectomy.  
With the aim to avoid unnecessary surgical complications, such studies should be performed 
only by skilled surgeons with experience in laparoscopic retroperitoneal dissection. In 
addition, we would recommend not occluding the utero-ovarian collaterals unless after 
appropriate counseling about the risk of ovarian damage.  
 
Contrast-enhanced MRI is a useful tool to evaluate the effect of vascular interventional 
treatment. However, the examination implicates considerable costs and is time-consuming 
and sometimes inconvenient for the patients. Simpler and less expensive methods such as 
color-Doppler ultrasound should be evaluated as an alternative tool.  
 
Patients with submucous leiomyomas that are treated with vascular interventional methods 
should be informed about the risk of leiomyoma expulsion and subsequent surgery. 
 
The temporary, Doppler-directed transvaginal uterine artery clamp needs further evaluation 
to clarify the efficacy and safety. 
 
 
 
 
 
 65
 66
10. REFERENCES 
Reference List 
 
 (1)  Day BD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative 
incidence of uterine leiomyoma in black and white women: ultrasound evidence. 
Am J Obstet Gynecol 2003; 188:100-107. 
 (2)  Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol 1990; 
94:435-438. 
 (3)  Buttram VC, Jr., Reiter RC. Uterine leiomyomata: etiology, symptomatology, and 
management. Fertil Steril 1981; 36:433-445. 
 (4)  Klatsky PC, Tran ND, Caughey AB, Fujimoto VY. Fibroids and reproductive 
outcomes: a systematic literature review from conception to delivery. Am J Obstet 
Gynecol 2008; 198:357-366. 
 (5)  Rice JP, Kay HH, Mahony BS. The clinical significance of uterine leiomyomas in 
pregnancy. Am J Obstet Gynecol 1989; 160:1212-1216. 
 (6)  Sheiner E, Bashiri A, Levy A, Hershkovitz R, Katz M, Mazor M. Obstetric 
characteristics and perinatal outcome of pregnancies with uterine leiomyomas. J 
Reprod Med 2004; 49:182-186. 
 (7)  Marshall LM, Spiegelman D, Goldman MB, et al. A prospective study of 
reproductive factors and oral contraceptive use in relation to the risk of uterine 
leiomyomata. Fertil Steril 1998; 70:432-439. 
 (8)  Flake GP, Andersen J, Dixon D. Etiology and pathogenesis of uterine leiomyomas: 
a review. Environ Health Perspect 2003; 111:1037-1054. 
 (9)  Marshall LM, Spiegelman D, Manson JE, et al. Risk of uterine leiomyomata 
among premenopausal women in relation to body size and cigarette smoking. 
Epidemiology 1998; 9:511-517. 
 (10)  Schwartz SM, Marshall LM, Baird DD. Epidemiologic contributions to 
understanding the etiology of uterine leiomyomata. Environ Health Perspect 2000; 
108 Suppl 5:821-827. 
 (11)  Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. Association of 
physical activity with development of uterine leiomyoma. Am J Epidemiol 2007; 
165:157-163. 
 (12)  Chiaffarino F, Parazzini F, La Vecchia C, Marsico S, Surace M, Ricci E. Use of 
oral contraceptives and uterine fibroids: results from a case-control study. Br J 
Obstet Gynaecol 1999; 106:857-860. 
 (13)  Chiaffarino F, Parazzini F, La Vecchia C, Ricci E, Crosignani PG. Oral 
contraceptive use and benign gynecologic conditions. A review. Contraception 
1998; 57:11-18. 
 67
 (14)  Wise LA, Palmer JR, Harlow BL, et al. Reproductive factors, hormonal 
contraception, and risk of uterine leiomyomata in African-American women: a 
prospective study. Am J Epidemiol 2004; 159:113-123. 
 (15)  Lumbiganon P, Rugpao S, Phandhu-fung S, Laopaiboon M, Vudhikamraksa N, 
Werawatakul Y. Protective effect of depot-medroxyprogesterone acetate on 
surgically treated uterine leiomyomas: a multicentre case--control study. Br J 
Obstet Gynaecol 1996; 103:909-914. 
 (16)  Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 micrograms/d 
and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. 
International Committee for Contraception Research (ICCR). Fertil Steril 1994; 
61:70-77. 
 (17)  Magalhaes J, Aldrighi JM, de Lima GR. Uterine volume and menstrual patterns in 
users of the levonorgestrel-releasing intrauterine system with idiopathic 
menorrhagia or menorrhagia due to leiomyomas. Contraception 2007; 75:193-198. 
 (18)  Marshall LM, Spiegelman D, Barbieri RL, et al. Variation in the incidence of 
uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol 
1997; 90:967-973. 
 (19)  Robbins SL, Angell M, Kumar V. The female Genital System and the Breast. In: 
Robbins SL, Angell M, Kumar V, editors. Basic Pathology. 3 ed. Philadelphia: 
W.B.Saunders Company; 1981. p. 574. 
 (20)  Robboy SJ, Bentley RC, Butnor K, Anderson MC. Pathology and pathophysiology 
of uterine smooth-muscle tumors. Environ Health Perspect 2000; 108 Suppl 5:779-
784. 
 (21)  Toledo G, Oliva E. Smooth muscle tumors of the uterus: a practical approach. 
Arch Pathol Lab Med 2008; 132:595-605. 
 (22)  Casey R, Rogers PA, Vollenhoven BJ. An immunohistochemical analysis of 
fibroid vasculature. Hum Reprod 2000; 15:1469-1475. 
 (23)  Kurjak A, Kupesic-Urek S, Miric D. The assessment of benign uterine tumor 
vascularization by transvaginal color Doppler. Ultrasound Med Biol 1992; 18:645-
649. 
 (24)  Forssman L. Blood flow in myomatous uteri as measured by intra-arterial 
133Xenon. Acta Obstet Gynecol Scand 1976; 55:21-24. 
 (25)  Forssman L. Distribution of blood flow in myomatous uteri as measured by locally 
injected 133Xenon. Acta Obstet Gynecol Scand 1976; 55:101-104. 
 (26)  Richards PA, Richards PD, Tiltman AJ. The ultrastructure of fibromyomatous 
myometrium and its relationship to infertility. Hum Reprod Update 1998; 4:520-
525. 
 (27)  Sampson JA. The blood supply of uterine myomata. Surg Gynecol Obstet 1912; 
14:215-230. 
 68
 (28)  Stewart EA. Uterine fibroids. Lancet 2001; 357:293-298. 
 (29)  Pavlovich CP, Schmidt LS. Searching for the hereditary causes of renal-cell 
carcinoma. Nat Rev Cancer 2004; 4:381-393. 
 (30)  Treloar SA, Martin NG, Dennerstein L, Raphael B, Heath AC. Pathways to 
hysterectomy: insights from longitudinal twin research. Am J Obstet Gynecol 
1992; 167:82-88. 
 (31)  Luoto R, Kaprio J, Rutanen EM, Taipale P, Perola M, Koskenvuo M. Heritability 
and risk factors of uterine fibroids--the Finnish Twin Cohort study. Maturitas 
2000; 37:15-26. 
 (32)  Snieder H, MacGregor AJ, Spector TD. Genes control the cessation of a woman's 
reproductive life: a twin study of hysterectomy and age at menopause. J Clin 
Endocrinol Metab 1998; 83:1875-1880. 
 (33)  Mashal RD, Fejzo ML, Friedman AJ, et al. Analysis of androgen receptor DNA 
reveals the independent clonal origins of uterine leiomyomata and the secondary 
nature of cytogenetic aberrations in the development of leiomyomata. Genes 
Chromosomes Cancer 1994; 11:1-6. 
 (34)  Hashimoto K, Azuma C, Kamiura S, et al. Clonal determination of uterine 
leiomyomas by analyzing differential inactivation of the X-chromosome-linked 
phosphoglycerokinase gene. Gynecol Obstet Invest 1995; 40:204-208. 
 (35)  Ligon AH, Morton CC. Genetics of uterine leiomyomata. Genes Chromosomes 
Cancer 2000; 28:235-245. 
 (36)  Rein MS. Advances in uterine leiomyoma research: the progesterone hypothesis. 
Environ Health Perspect 2000; 108 Suppl 5:791-793. 
 (37)  Richards PA, Tiltman AJ. Anatomical variation of the oestrogen receptor in the 
non-neoplastic myometrium of fibromyomatous uteri. Virchows Arch 1996; 
428:347-351. 
 (38)  Stewart EA, Nowak RA. New concepts in the treatment of uterine leiomyomas. 
Obstet Gynecol 1998; 92:624-627. 
 (39)  Wilson EA, Yang F, Rees ED. Estradiol and progesterone binding in uterine 
leiomyomata and in normal uterine tissues. Obstet Gynecol 1980; 55:20-24. 
 (40)  Tamaya T, Fujimoto J, Okada H. Comparison of cellular levels of steroid receptors 
in uterine leiomyoma and myometrium. Acta Obstet Gynecol Scand 1985; 64:307-
309. 
 (41)  Maruo T, Matsuo H, Samoto T, et al. Effects of progesterone on uterine 
leiomyoma growth and apoptosis. Steroids 2000; 65:585-592. 
 (42)  Otubu JA, Buttram VC, Besch NF, Besch PK. Unconjugated steroids in 
leiomyomas and tumor-bearing myometrium. Am J Obstet Gynecol 1982; 
143:130-133. 
 69
 (43)  Liehr JG, Ricci MJ, Jefcoate CR, Hannigan EV, Hokanson JA, Zhu BT. 4-
Hydroxylation of estradiol by human uterine myometrium and myoma 
microsomes: implications for the mechanism of uterine tumorigenesis. Proc Natl 
Acad Sci U S A 1995; 92:9220-9224. 
 (44)  Rein MS, Friedman AJ, Barbieri RL, Pavelka K, Fletcher JA, Morton CC. 
Cytogenetic abnormalities in uterine leiomyomata. Obstet Gynecol 1991; 77:923-
926. 
 (45)  Christacos NC, Quade BJ, Dal CP, Morton CC. Uterine leiomyomata with 
deletions of Ip represent a distinct cytogenetic subgroup associated with unusual 
histologic features. Genes Chromosomes Cancer 2006; 45:304-312. 
 (46)  Hodge JC, Morton CC. Genetic heterogeneity among uterine leiomyomata: 
insights into malignant progression. Hum Mol Genet 2007; 16 Spec No 1:R7-13. 
 (47)  Christopherson WM, Williamson EO, Gray LA. Leiomyosarcoma of the uterus. 
Cancer 1972; 29:1512-1517. 
 (48)  Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for 
presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol 1994; 
83:414-418. 
 (49)  Kahanpaa KV, Wahlstrom T, Grohn P, Heinonen E, Nieminen U, Widholm O. 
Sarcomas of the uterus: a clinicopathologic study of 119 patients. Obstet Gynecol 
1986; 67:417-424. 
 (50)  Berek J. HN. Sarcomas of the female genital tract. In: Eilber F. MDSVEJ, editor. 
The Soft Tissue Sarcomas. 1987. p. 229-38. 
 (51)  Pelage JP, Cazejust J, Pluot E, et al. Uterine fibroid vascularization and clinical 
relevance to uterine fibroid embolization. Radiographics 2005; 25 Suppl 1:S99-
117. 
 (52)  Holub Z, Lukac J, Kliment L, Urbanek S. Variability of the origin of the uterine 
artery: laparoscopic surgical observation. J Obstet Gynaecol Res 2005; 31:158-
163. 
 (53)  Farrer-Brown G, Beilby JO, Tarbit MH. The blood supply of the uterus. 1. Arterial 
vasculature. J Obstet Gynaecol Br Commonw 1970; 77:673-681. 
 (54)  Burchell RC, Olson G. Internal iliac artery ligation: aortograms. Am J Obstet 
Gynecol 1966; 94:117-124. 
 (55)  Chait A, Moltz A, Nelson JH, Jr. The collateral arterial circulation in the pelvis. 
An angiographic study. Am J Roentgenol Radium Ther Nucl Med 1968; 102:392-
400. 
 (56)  Karlsson S, Persson PH. Angiography in uterine and adnexal tumors. Acta Radiol 
Diagn (Stockh) 1980; 21:11-20. 
 70
 (57)  Razavi MK, Wolanske KA, Hwang GL, Sze DY, Kee ST, Dake MD. 
Angiographic classification of ovarian artery-to-uterine artery anastomoses: initial 
observations in uterine fibroid embolization. Radiology 2002; 224:707-712. 
 (58)  Kim HS, Tsai J, Patra A, Lee JM, Griffith JG, Wallach EE. Effects of utero-
ovarian anastomoses on clinical outcomes and repeat intervention rates after 
uterine artery embolization. J Vasc Interv Radiol 2006; 17:783-789. 
 (59)  Pelage JP, Walker WJ, Le DO, Rymer R. Ovarian artery: angiographic appearance, 
embolization and relevance to uterine fibroid embolization. Cardiovasc Intervent 
Radiol 2003; 26:227-233. 
 (60)  Kroencke TJ, Scheurig C, Kluner C, Taupitz M, Schnorr J, Hamm B. Uterine 
fibroids: contrast-enhanced MR angiography to predict ovarian artery supply--
initial experience. Radiology 2006; 241:181-189. 
 (61)  Borell U, Fernstrom I. The ovarian artery: an arteriographic study in human 
subjects. Acta Radiol 1954; 42:253-265. 
 (62)  Dueholm M, Lundorf E, Hansen ES, Ledertoug S, Olesen F. Accuracy of magnetic 
resonance imaging and transvaginal ultrasonography in the diagnosis, mapping, 
and measurement of uterine myomas. Am J Obstet Gynecol 2002; 186:409-415. 
 (63)  Spielmann AL, Keogh C, Forster BB, Martin ML, Machan LS. Comparison of 
MRI and sonography in the preliminary evaluation for fibroid embolization. AJR 
Am J Roentgenol 2006; 187:1499-1504. 
 (64)  Dueholm M, Lundorf E, Sorensen JS, Ledertoug S, Olesen F, Laursen H. 
Reproducibility of evaluation of the uterus by transvaginal sonography, 
hysterosonographic examination, hysteroscopy and magnetic resonance imaging. 
Hum Reprod 2002; 17:195-200. 
 (65)  Volkers NA, Hehenkamp WJ, Spijkerboer AM, et al. MR reproducibility in the 
assessment of uterine fibroids for patients scheduled for uterine artery 
embolization. Cardiovasc Intervent Radiol 2008; 31:260-268. 
 (66)  Reinhold C, McCarthy S, Bret PM, et al. Diffuse adenomyosis: comparison of 
endovaginal US and MR imaging with histopathologic correlation. Radiology 
1996; 199:151-158. 
 (67)  Byun JY, Kim SE, Choi BG, Ko GY, Jung SE, Choi KH. Diffuse and focal 
adenomyosis: MR imaging findings. Radiographics 1999; 19 Spec No:S161-S170. 
 (68)  Yamashita Y, Torashima M, Takahashi M, et al. Hyperintense uterine leiomyoma 
at T2-weighted MR imaging: differentiation with dynamic enhanced MR imaging 
and clinical implications. Radiology 1993; 189:721-725. 
 (69)  Zawin M, McCarthy S, Scoutt L, et al. Monitoring therapy with a gonadotropin-
releasing hormone analog: utility of MR imaging. Radiology 1990; 175:503-506. 
 (70)  Orsini LF, Salardi S, Pilu G, Bovicelli L, Cacciari E. Pelvic organs in 
premenarcheal girls: real-time ultrasonography. Radiology 1984; 153:113-116. 
 71
 (71)  Schlaff WD, Zerhouni EA, Huth JA, Chen J, Damewood MD, Rock JA. A 
placebo-controlled trial of a depot gonadotropin-releasing hormone analogue 
(leuprolide) in the treatment of uterine leiomyomata. Obstet Gynecol 1989; 
74:856-862. 
 (72)  Warner PE, Critchley HO, Lumsden MA, Campbell-Brown M, Douglas A, Murray 
GD. Menorrhagia II: is the 80-mL blood loss criterion useful in management of 
complaint of menorrhagia? Am J Obstet Gynecol 2004; 190:1224-1229. 
 (73)  Wallach EE, Vlahos NF. Uterine myomas: an overview of development, clinical 
features, and management. Obstet Gynecol 2004; 104:393-406. 
 (74)  Monga AK, Woodhouse CR, Stanton SL. Pregnancy and fibroids causing 
simultaneous urinary retention and ureteric obstruction. Br J Urol 1996; 77:606-
607. 
 (75)  Nevadunsky NS, Bachmann GA, Nosher J, Yu T. Women's decision-making 
determinants in choosing uterine artery embolization for symptomatic fibroids. J 
Reprod Med 2001; 46:870-874. 
 (76)  Lahteenmaki P, Haukkamaa M, Puolakka J, et al. Open randomised study of use of 
levonorgestrel releasing intrauterine system as alternative to hysterectomy. BMJ 
1998; 316:1122-1126. 
 (77)  Maruo T, Laoag-Fernandez JB, Pakarinen P, Murakoshi H, Spitz IM, Johansson E. 
Effects of the levonorgestrel-releasing intrauterine system on proliferation and 
apoptosis in the endometrium. Hum Reprod 2001; 16:2103-2108. 
 (78)  Maruo T, Ohara N, Matsuo H, et al. Effects of levonorgestrel-releasing IUS and 
progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas. 
Contraception 2007; 75:S99-103. 
 (79)  Friedman AJ, Hoffman DI, Comite F, Browneller RW, Miller JD. Treatment of 
leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-
controlled, multicenter study. The Leuprolide Study Group. Obstet Gynecol 1991; 
77:720-725. 
 (80)  Friedman AJ, Juneau-Norcross M, Rein MS. Adverse effects of leuprolide acetate 
depot treatment. Fertil Steril 1993; 59:448-450. 
 (81)  Leather AT, Studd JW, Watson NR, Holland EF. The prevention of bone loss in 
young women treated with GnRH analogues with "add-back" estrogen therapy. 
Obstet Gynecol 1993; 81:104-107. 
 (82)  Palomba S, Affinito P, Di CC, Bifulco G, Nappi C. Long-term administration of 
tibolone plus gonadotropin-releasing hormone agonist for the treatment of uterine 
leiomyomas: effectiveness and effects on vasomotor symptoms, bone mass, and 
lipid profiles. Fertil Steril 1999; 72:889-895. 
 (83)  Palomba S, Orio F, Jr., Russo T, et al. Long-term effectiveness and safety of 
GnRH agonist plus raloxifene administration in women with uterine leiomyomas. 
Hum Reprod 2004; 19:1308-1314. 
 72
 (84)  Nakayama H, Yano T, Sagara Y, et al. Estriol add-back therapy in the long-acting 
gonadotropin-releasing hormone agonist treatment of uterine leiomyomata. 
Gynecol Endocrinol 1999; 13:382-389. 
 (85)  Friedman AJ, Daly M, Juneau-Norcross M, Gleason R, Rein MS, LeBoff M. 
Long-term medical therapy for leiomyomata uteri: a prospective, randomized 
study of leuprolide acetate depot plus either oestrogen-progestin or progestin 'add-
back' for 2 years. Hum Reprod 1994; 9:1618-1625. 
 (86)  West CP, Lumsden MA, Lawson S, Williamson J, Baird DT. Shrinkage of uterine 
fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing 
hormone agonist administered as a monthly subcutaneous depot. Fertil Steril 1987; 
48:45-51. 
 (87)  Vercellini P, Maddalena S, De GO, Aimi G, Crosignani PG. Abdominal 
myomectomy for infertility: a comprehensive review. Hum Reprod 1998; 13:873-
879. 
 (88)  Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy 
before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst 
Rev 2000; CD000547. 
 (89)  Dubuisson JB, Fauconnier A, Fourchotte V, Babaki-Fard K, Coste J, Chapron C. 
Laparoscopic myomectomy: predicting the risk of conversion to an open 
procedure. Hum Reprod 2001; 16:1726-1731. 
 (90)  ACOG Committee Opinion. Uterine artery embolization. Obstet Gynecol 2004; 
103:403-404. 
 (91)  Campo S, Garcea N. Laparoscopic myomectomy in premenopausal women with 
and without preoperative treatment using gonadotrophin-releasing hormone 
analogues. Hum Reprod 1999; 14:44-48. 
 (92)  Vercellini P, Trespidi L, Zaina B, Vicentini S, Stellato G, Crosignani PG. 
Gonadotropin-releasing hormone agonist treatment before abdominal 
myomectomy: a controlled trial. Fertil Steril 2003; 79:1390-1395. 
 (93)  Farquhar C, Brown PM, Furness S. Cost effectiveness of pre-operative 
gonadotrophin releasing analogues for women with uterine fibroids undergoing 
hysterectomy or myomectomy. BJOG 2002; 109:1273-1280. 
 (94)  De Leo V, la Marca A, Morgante G. Short-term treatment of uterine fibromyomas 
with danazol. Gynecol Obstet Invest 1999; 47:258-262. 
 (95)  De Leo V, Morgante G, Lanzetta D, D'Antona D, Bertieri RS. Danazol 
administration after gonadotrophin-releasing hormone analogue reduces rebound 
of uterine myomas. Hum Reprod 1997; 12:357-360. 
 (96)  Coutinho EM, Goncalves MT. Long-term treatment of leiomyomas with 
gestrinone. Fertil Steril 1989; 51:939-946. 
 73
 (97)  Jirecek S, Lee A, Pavo I, Crans G, Eppel W, Wenzl R. Raloxifene prevents the 
growth of uterine leiomyomas in premenopausal women. Fertil Steril 2004; 
81:132-136. 
 (98)  Wu T, Chen X, Xie L. Selective estrogen receptor modulators (SERMs) for uterine 
leiomyomas. Cochrane Database Syst Rev 2007; CD005287. 
 (99)  Eisinger SH, Meldrum S, Fiscella K, le Roux HD, Guzick DS. Low-dose 
mifepristone for uterine leiomyomata. Obstet Gynecol 2003; 101:243-250. 
 (100)  Fiscella K, Eisinger SH, Meldrum S, Feng C, Fisher SG, Guzick DS. Effect of 
mifepristone for symptomatic leiomyomata on quality of life and uterine size: a 
randomized controlled trial. Obstet Gynecol 2006; 108:1381-1387. 
 (101)  Sankaran S, Manyonda IT. Medical management of fibroids. Best Pract Res Clin 
Obstet Gynaecol 2008; 22:655-676. 
 (102)  Chwalisz K, Brenner RM, Fuhrmann UU, Hess-Stumpp H, Elger W. 
Antiproliferative effects of progesterone antagonists and progesterone receptor 
modulators on the endometrium. Steroids 2000; 65:741-751. 
 (103)  Chwalisz K, Perez MC, Demanno D, Winkel C, Schubert G, Elger W. Selective 
progesterone receptor modulator development and use in the treatment of 
leiomyomata and endometriosis. Endocr Rev 2005; 26:423-438. 
 (104)  Chwalisz K, Larsen L, Mattia-Goldberg C, Edmonds A, Elger W, Winkel CA. A 
randomized, controlled trial of asoprisnil, a novel selective progesterone receptor 
modulator, in women with uterine leiomyomata. Fertil Steril 2007; 87:1399-1412. 
 (105)  Levens ED, Potlog-Nahari C, Armstrong AY, et al. CDB-2914 for uterine 
leiomyomata treatment: a randomized controlled trial. Obstet Gynecol 2008; 
111:1129-1136. 
 (106)  Kaunitz AM. Aromatase inhibitor therapy for uterine bleeding in a 
postmenopausal woman with leiomyomata. Menopause 2007; 14:941-943. 
 (107)  Melli MS, Farzadi L, Madarek EO. Comparison of the effect of gonadotropin-
releasing hormone analog (Diphereline) and Cabergoline (Dostinex) treatment on 
uterine myoma regression. Saudi Med J 2007; 28:445-450. 
 (108)  Moen MH. [Different practice in hysterectomy]. Tidsskr Nor Laegeforen 2004; 
124:767. 
 (109)  Garry R. The future of hysterectomy. BJOG 2005; 112:133-139. 
 (110)  Hirst A, Dutton S, Wu O, et al. A multi-centre retrospective cohort study 
comparing the efficacy, safety and cost-effectiveness of hysterectomy and uterine 
artery embolisation for the treatment of symptomatic uterine fibroids. The 
HOPEFUL study. Health Technol Assess 2008; 12:1-248, iii. 
 (111)  McPherson K, Metcalfe MA, Herbert A, et al. Severe complications of 
hysterectomy: the VALUE study. BJOG 2004; 111:688-694. 
 74
 (112)  Hillis SD, Marchbanks PA, Peterson HB. Uterine size and risk of complications 
among women undergoing abdominal hysterectomy for leiomyomas. Obstet 
Gynecol 1996; 87:539-543. 
 (113)  Wingo PA, Huezo CM, Rubin GL, Ory HW, Peterson HB. The mortality risk 
associated with hysterectomy. Am J Obstet Gynecol 1985; 152:803-808. 
 (114)   Agency for Healthcare Research and Quality 2009. Available from: URL: 
http://hcup.ahrq.gov/HCUPnet.asp 
 (115)  Goodwin SC, Bradley LD, Lipman JC, et al. Uterine artery embolization versus 
myomectomy: a multicenter comparative study. Fertil Steril 2006; 85:14-21. 
 (116)  Sawin SW, Pilevsky ND, Berlin JA, Barnhart KT. Comparability of perioperative 
morbidity between abdominal myomectomy and hysterectomy for women with 
uterine leiomyomas. Am J Obstet Gynecol 2000; 183:1448-1455. 
 (117)  West S, Ruiz R, Parker WH. Abdominal myomectomy in women with very large 
uterine size. Fertil Steril 2006; 85:36-39. 
 (118)  Iverson RE, Jr., Chelmow D, Strohbehn K, Waldman L, Evantash EG. Relative 
morbidity of abdominal hysterectomy and myomectomy for management of 
uterine leiomyomas. Obstet Gynecol 1996; 88:415-419. 
 (119)  Berkeley AS, DeCherney AH, Polan ML. Abdominal myomectomy and 
subsequent fertility. Surg Gynecol Obstet 1983; 156:319-322. 
 (120)  Starks GC. CO2 laser myomectomy in an infertile population. J Reprod Med 1988; 
33:184-186. 
 (121)  Tulandi T, Murray C, Guralnick M. Adhesion formation and reproductive outcome 
after myomectomy and second-look laparoscopy. Obstet Gynecol 1993; 82:213-
215. 
 (122)  Fauconnier A, Chapron C, Babaki-Fard K, Dubuisson JB. Recurrence of 
leiomyomata after myomectomy. Hum Reprod Update 2000; 6:595-602. 
 (123)  Seracchioli R, Rossi S, Govoni F, et al. Fertility and obstetric outcome after 
laparoscopic myomectomy of large myomata: a randomized comparison with 
abdominal myomectomy. Hum Reprod 2000; 15:2663-2668. 
 (124)  Dubuisson JB, Fauconnier A, Chapron C, Kreiker G, Norgaard C. Second look 
after laparoscopic myomectomy. Hum Reprod 1998; 13:2102-2106. 
 (125)  Nezhat FR, Roemisch M, Nezhat CH, Seidman DS, Nezhat CR. Recurrence rate 
after laparoscopic myomectomy. J Am Assoc Gynecol Laparosc 1998; 5:237-240. 
 (126)  Doridot V, Dubuisson JB, Chapron C, Fauconnier A, Babaki-Fard K. Recurrence 
of leiomyomata after laparoscopic myomectomy. J Am Assoc Gynecol Laparosc 
2001; 8:495-500. 
 75
 (127)  Mais V, Bracco GL, Litta P, Gargiulo T, Melis GB. Reduction of postoperative 
adhesions with an auto-crosslinked hyaluronan gel in gynaecological laparoscopic 
surgery: a blinded, controlled, randomized, multicentre study. Hum Reprod 2006; 
21:1248-1254. 
 (128)  Mais V, Ajossa S, Piras B, Guerriero S, Marongiu D, Melis GB. Prevention of de-
novo adhesion formation after laparoscopic myomectomy: a randomized trial to 
evaluate the effectiveness of an oxidized regenerated cellulose absorbable barrier. 
Hum Reprod 1995; 10:3133-3135. 
 (129)  Tsuji S, Takahashi K, Yomo H, et al. Effectiveness of antiadhesion barriers in 
preventing adhesion after myomectomy in patients with uterine leiomyoma. Eur J 
Obstet Gynecol Reprod Biol 2005; 123:244-248. 
 (130)  Mettler L, Audebert A, Lehmann-Willenbrock E, Schive-Peterhansl K, Jacobs VR. 
A randomized, prospective, controlled, multicenter clinical trial of a sprayable, 
site-specific adhesion barrier system in patients undergoing myomectomy. Fertil 
Steril 2004; 82:398-404. 
 (131)  Ofir K, Sheiner E, Levy A, Katz M, Mazor M. Uterine rupture: risk factors and 
pregnancy outcome. Am J Obstet Gynecol 2003; 189:1042-1046. 
 (132)  Nezhat F, Seidman DS, Nezhat C, Nezhat CH. Laparoscopic myomectomy today. 
Why, when and for whom? Hum Reprod 1996; 11:933-934. 
 (133)  Dubuisson JB, Chavet X, Chapron C, Gregorakis SS, Morice P. Uterine rupture 
during pregnancy after laparoscopic myomectomy. Hum Reprod 1995; 10:1475-
1477. 
 (134)  Dubuisson JB, Chapron C, Chavet X, Gregorakis SS. Fertility after laparoscopic 
myomectomy of large intramural myomas: preliminary results. Hum Reprod 1996; 
11:518-522. 
 (135)  Kumakiri J, Takeuchi H, Kitade M, et al. Pregnancy and delivery after 
laparoscopic myomectomy. J Minim Invasive Gynecol 2005; 12:241-246. 
 (136)  Campo S, Campo V, Gambadauro P. Reproductive outcome before and after 
laparoscopic or abdominal myomectomy for subserous or intramural myomas. Eur 
J Obstet Gynecol Reprod Biol 2003; 110:215-219. 
 (137)  Rossetti A, Sizzi O, Soranna L, Mancuso S, Lanzone A. Fertility outcome: long-
term results after laparoscopic myomectomy. Gynecol Endocrinol 2001; 15:129-
134. 
 (138)  Landi S, Fiaccavento A, Zaccoletti R, Barbieri F, Syed R, Minelli L. Pregnancy 
outcomes and deliveries after laparoscopic myomectomy. J Am Assoc Gynecol 
Laparosc 2003; 10:177-181. 
 (139)  Malzoni M, Sizzi O, Rossetti A, Imperato F. Laparoscopic myomectomy: a report 
of 982 procedures. Surg Technol Int 2006; 15:123-129. 
 76
 (140)  Soriano D, Dessolle L, Poncelet C, Benifla JL, Madelenat P, Darai E. Pregnancy 
outcome after laparoscopic and laparoconverted myomectomy. Eur J Obstet 
Gynecol Reprod Biol 2003; 108:194-198. 
 (141)  Wamsteker K, Emanuel MH, de Kruif JH. Transcervical hysteroscopic resection of 
submucous fibroids for abnormal uterine bleeding: results regarding the degree of 
intramural extension. Obstet Gynecol 1993; 82:736-740. 
 (142)  Campo S, Campo V, Gambadauro P. Short-term and long-term results of 
resectoscopic myomectomy with and without pretreatment with GnRH analogs in 
premenopausal women. Acta Obstet Gynecol Scand 2005; 84:756-760. 
 (143)  Vercellini P, Zaina B, Yaylayan L, Pisacreta A, De GO, Crosignani PG. 
Hysteroscopic myomectomy: long-term effects on menstrual pattern and fertility. 
Obstet Gynecol 1999; 94:341-347. 
 (144)  Emanuel MH, Wamsteker K, Hart AA, Metz G, Lammes FB. Long-term results of 
hysteroscopic myomectomy for abnormal uterine bleeding. Obstet Gynecol 1999; 
93:743-748. 
 (145)  Indman PD. Hysteroscopic treatment of menorrhagia associated with uterine 
leiomyomas. Obstet Gynecol 1993; 81:716-720. 
 (146)  Pritts EA. Fibroids and infertility: a systematic review of the evidence. Obstet 
Gynecol Surv 2001; 56:483-491. 
 (147)  Casini ML, Rossi F, Agostini R, Unfer V. Effects of the position of fibroids on 
fertility. Gynecol Endocrinol 2006; 22:106-109. 
 (148)  Heaston DK, Mineau DE, Brown BJ, Miller FJ, Jr. Transcatheter arterial 
embolization for control of persistent massive puerperal hemorrhage after bilateral 
surgical hypogastric artery ligation. AJR Am J Roentgenol 1979; 133:152-154. 
 (149)  Ravina JH, Herbreteau D, Ciraru-Vigneron N, et al. Arterial embolisation to treat 
uterine myomata. Lancet 1995; 346:671-672. 
 (150)  Burbank F, Hutchins FL. Uterine Artery Occlusion by Embolization or Surgery for 
the Treatment of Fibroids: A Unifying Hypothesis-Transient Uterine Ischemia. 
The Journal of the American Assosiation of Gynecologic Laparascopists 2000; 
7:1-49. 
 (151)  Hutchins FL, Jr., Worthington-Kirsch R, Berkowitz RP. Selective uterine artery 
embolization as primary treatment for symptomatic leiomyomata uteri. J Am 
Assoc Gynecol Laparosc 1999; 6:279-284. 
 (152)  Goodwin SC, McLucas B, Lee M, et al. Uterine artery embolization for the 
treatment of uterine leiomyomata midterm results. J Vasc Interv Radiol 1999; 
10:1159-1165. 
 (153)  Hovsepian DM, Siskin GP, Bonn J, et al. Quality improvement guidelines for 
uterine artery embolization for symptomatic leiomyomata. J Vasc Interv Radiol 
2004; 15:535-541. 
 77
 (154)  Nikolic B, Abbara S, Levy E, et al. Influence of radiographic technique and 
equipment on absorbed ovarian dose associated with uterine artery embolization. J 
Vasc Interv Radiol 2000; 11:1173-1178. 
 (155)  Worthington-Kirsch RL, Popky GL, Hutchins FL, Jr. Uterine arterial embolization 
for the management of leiomyomas: quality-of-life assessment and clinical 
response. Radiology 1998; 208:625-629. 
 (156)  Pelage JP, Le Dref O, Soyer P, et al. Fibroid-related menorrhagia: treatment with 
superselective embolization of the uterine arteries and midterm follow-up. 
Radiology 2000; 215:428-431. 
 (157)  Spies JB, Ascher SA, Roth AR, Kim J, Levy EB, Gomez-Jorge J. Uterine artery 
embolization for leiomyomata. Obstet Gynecol 2001; 98:29-34. 
 (158)  Andersen PE, Lund N, Justesen P, Munk T, Elle B, Floridon C. Uterine artery 
embolization of symptomatic uterine fibroida . Initial success and short-term 
results. Acta Radiol 2001; 42:234-238. 
 (159)  Walker WJ, Pelage JP. Uterine artery embolisation for symptomatic fibroids: 
clinical results in 400 women with imaging follow up. BJOG 2002; 109:1262-
1272. 
 (160)  Spies JB, Myers ER, Worthington-Kirsch R, Mulgund J, Goodwin S, Mauro M. 
The FIBROID Registry: symptom and quality-of-life status 1 year after therapy. 
Obstet Gynecol 2005; 106:1309-1318. 
 (161)  McLucas B, Adler L, Perrella R. Uterine fibroid embolization: nonsurgical 
treatment for symptomatic fibroids. J Am Coll Surg 2001; 192:95-105. 
 (162)  Brunereau L, Herbreteau D, Gallas S, et al. Uterine artery embolization in the 
primary treatment of uterine leiomyomas: technical features and prospective 
follow-up with clinical and sonographic examinations in 58 patients. AJR Am J 
Roentgenol 2000; 175:1267-1272. 
 (163)  Khaund A, Moss JG, McMillan N, Lumsden MA. Evaluation of the effect of 
uterine artery embolisation on menstrual blood loss and uterine volume. BJOG 
2004; 111:700-705. 
 (164)  Scheurig C, Gauruder-Burmester A, Kluner C, et al. Uterine artery embolization 
for symptomatic fibroids: short-term versus mid-term changes in disease-specific 
symptoms, quality of life and magnetic resonance imaging results. Hum Reprod 
2006; 21:3270-3277. 
 (165)  Spies JB, Bruno J, Czeyda-Pommersheim F, Magee ST, Ascher SA, Jha RC. 
Long-term outcome of uterine artery embolization of leiomyomata. Obstet 
Gynecol 2005; 106:933-939. 
 (166)  Walker WJ, Barton-Smith P. Long-term follow up of uterine artery embolisation--
an effective alternative in the treatment of fibroids. BJOG 2006; 113:464-468. 
 78
 (167)  Katsumori T, Kasahara T, Akazawa K. Long-term outcomes of uterine artery 
embolization using gelatin sponge particles alone for symptomatic fibroids. AJR 
Am J Roentgenol 2006; 186:848-854. 
 (168)  Worthington-Kirsch R, Spies JB, Myers ER, et al. The Fibroid Registry for 
outcomes data (FIBROID) for uterine embolization: short-term outcomes. Obstet 
Gynecol 2005; 106:52-59. 
 (169)  Vashisht A, Studd J, Carey A, Burn P. Fatal septicaemia after fibroid embolisation. 
Lancet 1999; 354:307-308. 
 (170)  de Blok S, de Vries C, Prinssen HM, Blaauwgeers HL, Jorna-Meijer LB. Fatal 
sepsis after uterine artery embolization with microspheres. J Vasc Interv Radiol 
2003; 14:779-783. 
 (171)  Lanocita R, Frigerio LF, Patelli G et al. A fatal complication of percutaneous 
transcatheter embolization for treatment of uterine fibroids. Milan, Italy: National 
Cancer Institute; 1999. 
 (172)  Parker WH. Uterine myomas: management. Fertil Steril 2007; 88:255-271. 
 (173)  Hehenkamp WJ, Volkers NA, Broekmans FJ, et al. Loss of ovarian reserve after 
uterine artery embolization: a randomized comparison with hysterectomy. Hum 
Reprod 2007; 22:1996-2005. 
 (174)  Burbank F. Are fibroids that become endocavitary after uterine artery embolization 
necessarily a complication? AJR Am J Roentgenol 2008; 190:1227-1230. 
 (175)  Agdi M, Valenti D, Tulandi T. Intraabdominal adhesions after uterine artery 
embolization. Am J Obstet Gynecol 2008; 199:482-483. 
 (176)  Walker WJ, McDowell SJ. Pregnancy after uterine artery embolization for 
leiomyomata: a series of 56 completed pregnancies. Am J Obstet Gynecol 2006; 
195:1266-1271. 
 (177)  Mara M, Maskova J, Fucikova Z, Kuzel D, Belsan T, Sosna O. Midterm clinical 
and first reproductive results of a randomized controlled trial comparing uterine 
fibroid embolization and myomectomy. Cardiovasc Intervent Radiol 2008; 31:73-
85. 
 (178)  Spies JB, Cornell C, Worthington-Kirsch R, Lipman JC, Benenati JF. Long-term 
outcome from uterine fibroid embolization with tris-acryl gelatin microspheres: 
results of a multicenter study. J Vasc Interv Radiol 2007; 18:203-207. 
 (179)  Spies JB, Allison S, Flick P, et al. Spherical polyvinyl alcohol versus tris-acryl 
gelatin microspheres for uterine artery embolization for leiomyomas: results of a 
limited randomized comparative study. J Vasc Interv Radiol 2005; 16:1431-1437. 
 (180)  Siskin GP, Beck A, Schuster M, Mandato K, Englander M, Herr A. Leiomyoma 
infarction after uterine artery embolization: a prospective randomized study 
comparing tris-acryl gelatin microspheres versus polyvinyl alcohol microspheres. J 
Vasc Interv Radiol 2008; 19:58-65. 
 79
 (181)  McLucas B, Adler L, Perella R. Predictive factors for success in uterine fibroid 
embolization. Minim Invasive Ther Allied Technol 1999; 8:429-432. 
 (182)  Watson GM, Walker WJ. Uterine artery embolisation for the treatment of 
symptomatic fibroids in 114 women: reduction in size of the fibroids and women's 
views of the success of the treatment. BJOG 2002; 109:129-135. 
 (183)  Spies JB, Roth AR, Jha RC, et al. Leiomyomata treated with uterine artery 
embolization: factors associated with successful symptom and imaging outcome. 
Radiology 2002; 222:45-52. 
 (184)  Jha RC, Ascher SM, Imaoka I, Spies JB. Symptomatic fibroleiomyomata: MR 
imaging of the uterus before and after uterine arterial embolization. Radiology 
2000; 217:228-235. 
 (185)  Isonishi S, Coleman RL, Hirama M, et al. Analysis of prognostic factors for 
patients with leiomyoma treated with uterine arterial embolization. Am J Obstet 
Gynecol 2008; 198:270-276. 
 (186)  Arleo EK, Masheb RM, Pollak J, McCarthy S, Tal MG. Fibroid volume, location 
and symptoms in women undergoing uterine artery embolization: does size or 
position matter? Int J Fertil Womens Med 2007; 52:111-120. 
 (187)  Harman M, Zeteroglu S, Arslan H, Sengul M, Etlik O. Predictive value of 
magnetic resonance imaging signal and contrast-enhancement characteristics on 
post-embolization volume reduction of uterine fibroids. Acta Radiol 2006; 47:427-
435. 
 (188)  Burn PR, McCall JM, Chinn RJ, Vashisht A, Smith JR, Healy JC. Uterine 
fibroleiomyoma: MR imaging appearances before and after embolization of 
uterine arteries. Radiology 2000; 214:729-734. 
 (189)  Kroencke TJ, Scheurig C, Lampmann LE, et al. Acrylamido polyvinyl alcohol 
microspheres for uterine artery embolization: 12-month clinical and MR imaging 
results. J Vasc Interv Radiol 2008; 19:47-57. 
 (190)  Pelage JP, Guaou NG, Jha RC, Ascher SM, Spies JB. Uterine fibroid tumors: long-
term MR imaging outcome after embolization. Radiology 2004; 230:803-809. 
 (191)  Katsumori T, Kasahara T, Kin Y, Nozaki T. Infarction of uterine fibroids after 
embolization: relationship between postprocedural enhanced MRI findings and 
long-term clinical outcomes. Cardiovasc Intervent Radiol 2008; 31:66-72. 
 (192)  Gabriel-Cox K, Jacobson GF, Armstrong MA, Hung YY, Learman LA. Predictors 
of hysterectomy after uterine artery embolization for leiomyoma. Am J Obstet 
Gynecol 2007; 196:588-6. 
 (193)  McLucas B, Adler L. Uterine fibroid embolization compared with myomectomy. 
Int J Gynaecol Obstet 2001; 74:297-299. 
 80
 (194)  Razavi MK, Hwang G, Jahed A, Modanloo S, Chen B. Abdominal myomectomy 
versus uterine fibroid embolization in the treatment of symptomatic uterine 
leiomyomas. AJR Am J Roentgenol 2003; 180:1571-1575. 
 (195)  Siskin GP, Shlansky-Goldberg RD, Goodwin SC, et al. A prospective multicenter 
comparative study between myomectomy and uterine artery embolization with 
polyvinyl alcohol microspheres: long-term clinical outcomes in patients with 
symptomatic uterine fibroids. J Vasc Interv Radiol 2006; 17:1287-1295. 
 (196)  Siskin GP, Shlansky-Goldberg RD, Goodwin SC, et al. A prospective multicenter 
comparative study between myomectomy and uterine artery embolization with 
polyvinyl alcohol microspheres: long-term clinical outcomes in patients with 
symptomatic uterine fibroids. J Vasc Interv Radiol 2006; 17:1287-1295. 
 (197)  Pinto I, Chimeno P, Romo A, et al. Uterine fibroids: uterine artery embolization 
versus abdominal hysterectomy for treatment--a prospective, randomized, and 
controlled clinical trial. Radiology 2003; 226:425-431. 
 (198)  Hehenkamp WJ, Volkers NA, Birnie E, Reekers JA, Ankum WM. Pain and return 
to daily activities after uterine artery embolization and hysterectomy in the 
treatment of symptomatic uterine fibroids: results from the randomized EMMY 
trial. Cardiovasc Intervent Radiol 2006; 29:179-187. 
 (199)  Edwards RD, Moss JG, Lumsden MA, et al. Uterine-artery embolization versus 
surgery for symptomatic uterine fibroids. N Engl J Med 2007; 356:360-370. 
 (200)  Dutton S, Hirst A, McPherson K, Nicholson T, Maresh M. A UK multicentre 
retrospective cohort study comparing hysterectomy and uterine artery embolisation 
for the treatment of symptomatic uterine fibroids (HOPEFUL study): main results 
on medium-term safety and efficacy. BJOG 2007; 114:1340-1351. 
 (201)  Al-Fozan H, Dufort J, Kaplow M, Valenti D, Tulandi T. Cost analysis of 
myomectomy, hysterectomy, and uterine artery embolization. Am J Obstet 
Gynecol 2002; 187:1401-1404. 
 (202)  Wu O, Briggs A, Dutton S, et al. Uterine artery embolisation or hysterectomy for 
the treatment of symptomatic uterine fibroids: a cost-utility analysis of the 
HOPEFUL study. BJOG 2007; 114:1352-1362. 
 (203)  Volkers NA, Hehenkamp WJ, Smit P, Ankum WM, Reekers JA, Birnie E. 
Economic evaluation of uterine artery embolization versus hysterectomy in the 
treatment of symptomatic uterine fibroids: results from the randomized EMMY 
trial. J Vasc Interv Radiol 2008; 19:1007-1016. 
 (204)  Beinfeld MT, Bosch JL, Isaacson KB, Gazelle GS. Cost-effectiveness of uterine 
artery embolization and hysterectomy for uterine fibroids. Radiology 2004; 
230:207-213. 
 (205)  You JH, Sahota DS, Yuen PM. Uterine artery embolization, hysterectomy, or 
myomectomy for symptomatic uterine fibroids: a cost-utility analysis. Fertil Steril 
2009; 91:580-588. 
 81
 (206)  Nisolle M, Smets M, Malvaux V, Anaf V, Donnez J. Laparoscopic myolysis with 
the Nd:YAG laser. J Gynecol Surg 1993; 9:95-99. 
 (207)  Zupi E, Piredda A, Marconi D, et al. Directed laparoscopic cryomyolysis: a 
possible alternative to myomectomy and/or hysterectomy for symptomatic 
leiomyomas. Am J Obstet Gynecol 2004; 190:639-643. 
 (208)  Kanaoka Y, Yoshida C, Fukuda T, Kajitani K, Ishiko O. Transcervical microwave 
myolysis for uterine myomas assisted by transvaginal ultrasonic guidance. J Obstet 
Gynaecol Res 2009; 35:145-151. 
 (209)  Zupi E, Marconi D, Sbracia M, et al. Directed laparoscopic cryomyolysis for 
symptomatic leiomyomata: one-year follow up. J Minim Invasive Gynecol 2005; 
12:343-346. 
 (210)  Cho HH, Kim JH, Kim MR. Transvaginal radiofrequency thermal ablation: a day-
care approach to symptomatic uterine myomas. Aust N Z J Obstet Gynaecol 2008; 
48:296-301. 
 (211)  Ciavattini A, Tsiroglou D, Litta P, Vichi M, Tranquilli AL. Pregnancy outcome 
after laparoscopic cryomyolysis of uterine myomas: report of nine cases. J Minim 
Invasive Gynecol 2006; 13:141-144. 
 (212)  Donnez J, Squifflet J, Polet R, Nisolle M. Laparoscopic myolysis. Hum Reprod 
Update 2000; 6:609-613. 
 (213)  Stewart EA, Gedroyc WM, Tempany CM, et al. Focused ultrasound treatment of 
uterine fibroid tumors: safety and feasibility of a noninvasive thermoablative 
technique. Am J Obstet Gynecol 2003; 189:48-54. 
 (214)  Stewart EA, Gostout B, Rabinovici J, Kim HS, Regan L, Tempany CM. Sustained 
relief of leiomyoma symptoms by using focused ultrasound surgery. Obstet 
Gynecol 2007; 110:279-287. 
 (215)  Kuhn P. Om Underbinding af aa.uterinæ ved fibroma uteri. Nordiskt Medisinskt 
Arkiv 1895; 1-12. 
 (216)  Bateman W. Treatment of Intractable Menorrhagia by Bilateral Uterine Vessel 
Interruption. Am J Obstet Gynecol 1964; 89:825-827. 
 (217)  Liu WM. Laparoscopic bipolar coagulation of uterine vessels to treat symptomatic 
leiomyomas. J Am Assoc Gynecol Laparosc 2000; 7:125-129. 
 (218)  Liu WM, Ng HT, Wu YC, Yen YK, Yuan CC. Laparoscopic bipolar coagulation 
of uterine vessels: a new method for treating symptomatic fibroids. Fertil Steril 
2001; 75:417-422. 
 (219)  Lichtinger M, Hallson L, Calvo P, Adeboyejo G. Laparoscopic uterine artery 
occlusion for symptomatic leiomyomas. J Am Assoc Gynecol Laparosc 2002; 
9:191-198. 
 82
 (220)  Park KH, Kim JY, Shin JS, et al. Treatment outcomes of uterine artery 
embolization and laparoscopic uterine artery ligation for uterine myoma. Yonsei 
Med J 2003; 44:694-702. 
 (221)  Holub Z, Jabor A, Lukac J, Kliment L, Urbanek S. Midterm follow-up study of 
laparoscopic dissection of uterine vessels for surgical treatment of symptomatic 
fibroids. Surg Endosc 2004; 18:1349-1353. 
 (222)  Holub Z, Eim J, Jabor A, Hendl A, Lukac J, Kliment L. Complications and myoma 
recurrence after laparoscopic uterine artery occlusion for symptomatic myomas. J 
Obstet Gynaecol Res 2006; 32:55-62. 
 (223)  Wang PH, Liu WM, Fuh JL, Chao HT, Chao KC, Yuan CC. Laparoscopic uterine 
vessel occlusion in the treatment of women with symptomatic uterine myomas 
with and without adding laparoscopic myomectomy: 4-year results. J Minim 
Invasive Gynecol 2008; 15:712-718. 
 (224)  Chen YJ, Wang PH, Yuan CC, et al. Pregnancy following treatment of 
symptomatic myomas with laparoscopic bipolar coagulation of uterine vessels. 
Hum Reprod 2003; 18:1077-1081. 
 (225)  Holub Z, Lukac J, Kliment L, Urbanek S. Pregnancy outcomes and deliveries 
following laparoscopic transsection of uterine vessels: a pilot study. Eur J Obstet 
Gynecol Reprod Biol 2006; 125:165-170. 
 (226)  Holub Z, Mara M, Eim J. Laparoscopic uterine artery occlusion versus uterine 
fibroid embolization. Int J Gynaecol Obstet 2007; 96:44-45. 
 (227)  Dickner SK, Cooper JM, Diaz D. A nonincisional, Doppler-guided transvaginal 
approach to uterine artery identification and control of uterine perfusion. J Am 
Assoc Gynecol Laparosc 2004; 11:55-58. 
 (228)  Rasmussen J, Roberts HR, Astrup T. Fibrinolytic activity of the normal and 
fibromyamatous human uterus. Surg Gynecol Obstet 1964; 118:1277-1280. 
 (229)  Colman RW, Hirsh J, Marder VJ. Hemostasis and Thrombosis. Basic Principles 
and Clinical Practice. 4 ed. Lippincott Williams & Wilkins; 2001. 
 (230)  Vott S, Bonilla SM, Goodwin SC, et al. CT findings after uterine artery 
embolization. J Comput Assist Tomogr 2000; 24:846-848. 
 (231)  deSouza NM, Williams AD. Uterine arterial embolization for leiomyomas: 
perfusion and volume changes at MR imaging and relation to clinical outcome. 
Radiology 2002; 222:367-374. 
 (232)  Farrer-Brown G, Beilby JO, Tarbit MH. The vascular patterns in myomatous uteri. 
J Obstet Gynaecol Br Commonw 1970; 77:967-975. 
 (233)  Lichtinger M, Hallson L, Calvo PAG. The Course of Uterine Myometrial 
Perfusion after Laparascopic Occlusion of Uterine Arteries for Symptomatic 
Leiomyomas. The Journal of the American Assosiation of Gynecologic 
Laparascopists 2002; 9:32-33. 
 83
 (234)  Lichtinger M, Herbert S, Memmolo A. Temporary, transvaginal occlusion of the 
uterine arteries: a feasibility and safety study. J Minim Invasive Gynecol 2005; 
12:40-42. 
 (235)  Broekmans FJ, Heitbrink MA, Hompes PG, Schoute E, Falke T, Schoemaker J. 
Quantitative MRI of uterine leiomyomas during triptorelin treatment: 
reproducibility of volume assessment and predictability of treatment response. 
Magn Reson Imaging 1996; 14:1127-1135. 
 (236)  Peto R. Failure of randomisation by "sealed" envelope. Lancet 1999; 354:73. 
 (237)  Reid PC, Coker A, Coltart R. Assessment of menstrual blood loss using a pictorial 
chart: a validation study. BJOG 2000; 107:320-322. 
 (238)  Janssen CA, Scholten PC, Heintz AP. A simple visual assessment technique to 
discriminate between menorrhagia and normal menstrual blood loss. Obstet 
Gynecol 1995; 85:977-982. 
 (239)  Goodwin SC, Bonilla SC, Sacks D, et al. Reporting standards for uterine artery 
embolization for the treatment of uterine leiomyomata. J Vasc Interv Radiol 2003; 
14:S467-S476. 
 (240)  Higham JM, O'Brien PM, Shaw RW. Assessment of menstrual blood loss using a 
pictorial chart. Br J Obstet Gynaecol 1990; 97:734-739. 
 (241)  Speroff L, Glass RH, Kase NG. Regulation of the Menstrual Cycle. In: Mitchell C, 
editor. Clinical Gynecology Endocrinology and Infertility. 5 ed. Baltimore,USA: 
Williams & Wilkins; 1994. p. 183-220. 
 (242)  Scott RT, Toner JP, Muasher SJ, Oehninger S, Robinson S, Rosenwaks Z. Follicle-
stimulating hormone levels on cycle day 3 are predictive of in vitro fertilization 
outcome. Fertil Steril 1989; 51:651-654. 
 (243)  van Rooij I, Broekmans FJ, Te Velde ER, et al. Serum anti-Mullerian hormone 
levels: a novel measure of ovarian reserve. Hum Reprod 2002; 17:3065-3071. 
 (244)  Hehenkamp WJ, Looman CW, Themmen AP, de Jong FH, Te Velde ER, 
Broekmans FJ. Anti-Mullerian hormone levels in the spontaneous menstrual cycle 
do not show substantial fluctuation. J Clin Endocrinol Metab 2006; 91:4057-4063. 
 (245)  Holub Z, Jabor A, Hendl J, Lukac J, Kliment L, Urbanek S. Effects of selective 
blockage of utero-ovarian anastomoses on clinical results of uterine artery 
occlusion. JSLS 2007; 11:309-314. 
 (246)  Spies JB, Scialli AR, Jha RC, et al. Initial results from uterine fibroid embolization 
for symptomatic leiomyomata. J Vasc Interv Radiol 1999; 10:1149-1157. 
 (247)  Pelage JP, Laurent A, Wassef M, et al. Uterine artery embolization in sheep: 
comparison of acute effects with polyvinyl alcohol particles and calibrated 
microspheres. Radiology 2002; 224:436-445. 
 84
 (248)  Chua GC, Wilsher M, Young MP, Manyonda I, Morgan R, Belli AM. Comparison 
of particle penetration with non-spherical polyvinyl alcohol versus trisacryl gelatin 
microspheres in women undergoing premyomectomy uterine artery embolization. 
Clin Radiol 2005; 60:116-122. 
 (249)  Pelage JP. Polyvinyl alcohol particles versus tris-acryl gelatin microspheres for 
uterine artery embolization for leiomyomas. J Vasc Interv Radiol 2004; 15:789-
791. 
 (250)  Spies JB, Allison S, Flick P, et al. Polyvinyl alcohol particles and tris-acryl gelatin 
microspheres for uterine artery embolization for leiomyomas: results of a 
randomized comparative study. J Vasc Interv Radiol 2004; 15:793-800. 
 (251)  Pelage JP, Le DO, Beregi JP, et al. Limited uterine artery embolization with tris-
acryl gelatin microspheres for uterine fibroids. J Vasc Interv Radiol 2003; 14:15-
20. 
 (252)  Ryu RK, Omary RA, Sichlau MJ, et al. Comparison of pain after uterine artery 
embolization using tris-acryl gelatin microspheres versus polyvinyl alcohol 
particles. Cardiovasc Intervent Radiol 2003; 26:375-378. 
 (253)  Bruno J, Sterbis K, Flick P, et al. Recovery after uterine artery embolization for 
leiomyomas: a detailed analysis of its duration and severity. J Vasc Interv Radiol 
2004; 15:801-807. 
 (254)  Fergusson D, Aaron SD, Guyatt G, Hebert P. Post-randomisation exclusions: the 
intention to treat principle and excluding patients from analysis. BMJ 2002; 
325:652-654. 
 (255)  Warner PE, Critchley HO, Lumsden MA, Campbell-Brown M, Douglas A, Murray 
GD. Menorrhagia I: measured blood loss, clinical features, and outcome in women 
with heavy periods: a survey with follow-up data. Am J Obstet Gynecol 2004; 
190:1216-1223. 
 (256)  Makinen J, Johansson J, Tomas C, et al. Morbidity of 10 110 hysterectomies by 
type of approach. Hum Reprod 2001; 16:1473-1478. 
 (257)  Czeyda-Pommersheim F, Magee ST, Cooper C, Hahn WY, Spies JB. Venous 
thromboembolism after uterine fibroid embolization. Cardiovasc Intervent Radiol 
2006; 29:1136-1140. 
 (258)  Spies JB, Spector A, Roth AR, Baker CM, Mauro L, Murphy-Skrynarz K. 
Complications after uterine artery embolization for leiomyomas. Obstet Gynecol 
2002; 100:873-880. 
 (259)  Burchell RC. Physiology of internal iliac artery ligation. J Obstet Gynaecol Br 
Commonw 1968; 75:642-651. 
 (260)  Torigian DA, Siegelman ES, Terhune KP, Butts SF, Blasco L, Shlansky-Goldberg 
RD. MRI of uterine necrosis after uterine artery embolization for treatment of 
uterine leiomyomata. AJR Am J Roentgenol 2005; 184:555-559. 
 85
 (261)  Abbara S, Spies JB, Scialli AR, Jha RC, Lage JM, Nikolic B. Transcervical 
expulsion of a fibroid as a result of uterine artery embolization for leiomyomata. J 
Vasc Interv Radiol 1999; 10:409-411. 
 (262)  Verma SK, Bergin D, Gonsalves CF, Mitchell DG, Lev-Toaff AS, Parker L. 
Submucosal fibroids becoming endocavitary following uterine artery 
embolization: risk assessment by MRI. AJR Am J Roentgenol 2008; 190:1220-
1226. 
 (263)  Al-Fozan H, Tulandi T. Factors affecting early surgical intervention after uterine 
artery embolization. Obstet Gynecol Surv 2002; 57:810-815. 
 (264)  Hehenkamp WJ, Volkers NA, Van Swijndregt AD, de Blok S, Reekers JA, Ankum 
WM. Myoma expulsion after uterine artery embolization: complication or cure? 
Am J Obstet Gynecol 2004; 191:1713-1715. 
 (265)  Katz M. Setting Up a Multivariable Analysis. In: Katz M, editor. Multivariable 
analysis: a practical guide for clinicians. 2nd ed. ed. Cambridge: Cambridge 
University Press; 2006. p. 77-81. 
 (266)  Toor SS, Tan KT, Simons ME, et al. Clinical failure after uterine artery 
embolization: evaluation of patient and MR imaging characteristics. J Vasc Interv 
Radiol 2008; 19:662-667. 
 
 
 
 86
 87
11. CORRECTIONS
Paper I.  
 
Abstract, page 37: “Postoperative pain and use of pain relief differed significantly,” should 
be: “Postoperative use of pain relief differed significantly,” 
 
Abstract, page 37: P = .008, should be: P = .00 
 
Material and methods, page 38: “The patients were followed at the outpatient clinic with 
visits scheduled at 6 weeks, 3 and 6 months after the operation”, should be “The patients 
were followed at the outpatient clinic with visits scheduled at 4 weeks, 3 and 6 months after 
the operation.”  
 
Material and methods, page 38: Uterine bleeding was quantified by the semiquantitative 
pictorial blood loss assessment score (PBAC), completed by all subjects over a screening 
period of 2 months before enrolment, should be “Uterine bleeding was quantified by the 
semiquantitative pictorial blood loss assessment score (PBAC), completed by all subjects 
during one menstrual period before enrolment.” 
 
 
 
 

I
This article is removed.  
II
This article is removed.  
III
This article is removed.  
IV
This article is removed.  
V
This article is removed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 

Pictorial Blood loss Assessment Chart, Norwegian version 

